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Abstract
Peripheral blood monocytes and tissue macrophages play critical roles in both 
the natural history and the pathogenesis of HIV-1 infection. This thesis mainly 
focused on the study of a potential defensive role of macrophages in HIV-1 
infection.
HIV-1 expression in monocyte-derived macrophages (MDM) infected in 
vitro is known to be inhibited by lypopolysaccharide (LPS), the main 
component of the bacterial cell wall. However, the mechanisms are not 
completely understood. We show herein that LPS protects primary 
macrophages from infection by CCR5-dependent HIV-1 isolates. Inhibition was 
largely mediated by the release of the C-C chemokines RANTES, MDMa and 
MTP-lp. Indeed, (a) addition of LPS to MDM resulted in the vigorous production 
of RANTES, MDMa and MIP-1P; (b) high levels of CCR5, the C-C chemokine 
receptor, were expressed by MDM at the time of infection; (c) antibody- 
mediated depletion of RANTES, MDMa and MDM(3 neutralized the ability of 
LPS-conditioned supernatants to inhibit HIV-1 replication in MDM; (d) a 
combination of recombinant RANTES, MDMa and MDMp blocked HIV-1 
infection as effectively as LPS itself.
CXCR4 mediates the entry of syncytia-inducing strains, both primary 
and T cell line-adapted. The ability of SI HIV-1 isolates to infect primary human 
macrophages has been disputed. Here, we report that CXCR4 expression on 
human MDM was variable but consistently significant. Primary CXCR4- 
dependent HIV-1 strains infected MDM productively and were specifically 
blocked by SDF 1» By contrast MDM supported the entry but not the replication 
of CXCR4-dependent TCLA HIV strains. Thus, monocyte/macrophages
support the entry and replication not only of CCRS-dependent, but also of 
CXCR4-dependent primary HIV-1 isolates.
Because CXCR4 is a functional coreceptor for HIV-1 infection of human 
macrophages, we investigated whether LPS also affects the replication of 
CXCR4-dependent HIV-1 isolates. Our results show that LPS inhibits the 
replication of X4 HIV-1 isolates in MDM through the release of novel soluble 
suppressive factor(s) that are as of yet uncharacterized.
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21 Introduction
1.1 HIV-l
i
In the early 1980s, reports from the United States described an increased 
incidence of Pneumocystis carinii pneumonia and an aggressive form of 
Kaposi's sarcoma in previously healthy young homosexual men [77, 78, 155]. 
Because a common finding in these patients was a depletion of CD4+ T 
lymphocytes, the symptoms were ascribed to immunosuppression. The new 
disease was termed "acquired immunodeficiency syndrome" (AIDS) [79]. 
Within 2 years, the aetiological agent was isolated by three independent 
laboratories and referred to as lymphadenopathy-associated virus (LAV), 
human T-lymphotropic virus m  (HTLV-HI), and AIDS-related retrovirus 
(ARV) [22, 134, 221]. This novel agent was subsequently renamed hum an 
immunodeficiency virus type 1 (HTV-l) [68]. HIV-l was shown to be 
transmitted via sexual contact and blood products, as well as from mother to 
child. The number of reported AIDS cases increased dramatically in the 
following years and HTV-l-infected individuals were also diagnosed in Europe 
and Central Africa [66, 80], in addition to the United States. HIV-l infection has 
since then spread to all continents, affecting people regardless of race, sex or 
age.
Despite the fact that AIDS was first described in the United States and 
later in Europe, HTV-l is believed to have originated from Africa [263]. In 1986, 
an antigenic variant of HIV-l, called HIV-2, was isolated from patients with 
AIDS-like illnesses living in Guinea-Bissau and other neighbouring countries 
of West Africa [65]. HIV-2 appears to be less transmissible and pathogenic than 
HIV-l [390]. Characterization of antibodies in stored sera showed that reactivity
against HTV-l and HIV-2 could be detected in Africa as early as 1959 [263] and 
1966 [190], respectively. Further evidence for the African origin of HIV-l came 
through the identification of the simian immunodeficiency viruses (SIVs), 
which are phylogenetically related to HTV-l and HIV-2. Monkeys infected in 
the wild - such as Sooty mangabeys, Sykes, and African green monkeys - all 
harbour their own STV variant (STVsm, STVsyk, or STVagm) [130,188, 258, 368]. 
In addition a lentivirus designed STVcpz has been found in chimpanzees [282]. 
STV infection does not appear to cause immunodeficiency in natural hosts 
[140]. By contrast, SIV isolates from several Asian macaque species held in 
captivity in primate research facilities in the United States, including SIV from 
rhesus macaques (STVmac) and nemestrina macaques (STVmnz), cause a fatal 
AIDS-like disease [86,219,258].
When viral genomes were compared at the nucleotide level, it was 
reported that HIV-l and HIV-2 strains generally exhibit only around 40% 
homology [161], while HIV-2 is more closely related to certain SIV variants, 
such as STVsm [129]. Cross-species transmission of STV from monkeys to 
humans has been proposed as the origin of both HTV-l and HIV-2 [184, 282]. A 
virus (STVsm) that is genomically undistinguishable from HIV-2 was found in 
substantial numbers of wild-living sooty mangabeys whose natural habitat 
coincides with the epicentre of the HIV-2 epidemic [55, 137,173]. Regardless of 
the origin of HTV-l, a recent paper documented that two chimpanzee 
subspecies found in central and eastern Africa, P.t. troglodytes and P.t. 
schweinfurthii, harbour SIVcpz. The viruses isolated from the two subspecies 
form two highly divergent phylogenetic lineages. Interestingly all the HTV-l 
strains known to infect humans, including HIV-l groups M, N and O, are 
phylogenetically closely related to STVcpz strains that infect P.t. troglodytes, a
primate whose natural range coincides precisely with areas of HTV-l group M, 
N, and O endemicity. Chimpanzees are commonly hunted and butchered, 
especially in west equatorial Africa, and as a consequence represent a ready 
source for zoonotic transmission of STVcpz to man [135].
1.1.1 In vivo  HIV-l infection
The major target for HTV-l infection are cells that express the CD4 surface 
antigen. CD4 normally functions as a ligand for major histocompatibility 
complex (MHC) class II molecules during antigen presentation, and is 
expressed on T-helper cells and cells of the mononuclear phagocytic lineage 
including monocytes, macrophages, dendritic cells, and brain microglial cells. 
HTV infection of CD4-negative cells has also been reported [50, 62, 203, 210, 223, 
305], but it is usually much less efficient than infection of CD4+ cells. Sexual 
transmission of HIV-l occurs through mucosal surfaces and is the major route 
of infection worldwide. Analysis of genital biopsies from HIV-infected women 
has demonstrated that subepithelial macrophages represent the main target 
cells for HIV infection in the female genital tract [158]. Whether intact genital 
epithelium is a barrier to, or an active participant in HTV transmission has not 
been elucidated so far [38,180].
HTV disease may be divided into three phases: a) primary infection b) 
clinical latency and c) clinically apparent disease culminating in AIDS. During 
primary infection, the virus has been found to rapidly travel from the port of 
entry (the bloodstream and/or mucosal surfaces) to regional and then distal 
lymph nodes, where it is trapped on the surface of follicular dendritic cells. 
Lymphoid tissue represents a major reservoir for the virus in infected 
individuals, and viral replication occurs in this tissue throughout the course of
infection [278]. Upon primary infection with HTV-l, patients may develop an 
influenza-like or acute mononucleosis-like illness. The period shortly after 
primary infection is marked by high numbers of virions and virus-infected 
cells in the blood accompanied by transient CD4 lymphocytopenia. Following 
the appearance of anti-HTV-1 antibodies (seroconversion) the viral load 
commonly decreases, probably as a result of increasing cytotoxic T lymphocyte 
(CTL) activity. The subsequent clinically asymptomatic period can last for 
several years. Subsequently, the viral load increases again and the number of 
CD4+ T cells slowly declines. Gradual quantitative and qualitative loss of 
effector cell functions causes an impairment of both cellular and humoral 
immune responses. The resulting generalized immunodeficiency ultimately 
leads to the development of opportunistic infections, neurological disorders, or 
neoplasias such as Kaposi's sarcoma or B-cell lymphomas.
The median time from primary HTV-l. infection to the development of 
AIDS is approximately 10 years; however, the course of the disease can range 
from rapidly progressive to long-term asymptomatic (>10 years). The 
conditions underlying the long-term asymptomatic state have been the focus 
of intense investigation. The strongest prognostic marker identified to date is 
viral load [243, 244]. Indeed, long-term non-progressors (LTNPs) are 
characterized by low levels of virus in cells and plasma, vigorous im m une 
responses, both humoral and cellular, a stable CD4 count, and no signs of 
symptoms of disease for many years [220, 335]. A few LTNPs have been found 
to harbour viruses defective in their accessory genes, most commonly nef [41]. 
It has been proposed that these virus variants may have a reduced replicative 
capacity in vivo. By contrast, rapid progressors show a rapid increase in viral
load and a parallel decline in CD4 counts, and consequently progress to disease 
faster than other infected individuals [110, 191, 200].
The level of HIV replication in patients is strongly influenced by both 
viral and host factors. Among the latter, the endogenous cytokines that control 
the homeostasis of the immune system, as well as inflammatory and immune- 
mediated reactions, play a very important foie [117, 293]. In HIV-infected 
individuals there is increased secretion of the proinflammatory cytokines 
TNF-a, IL-6 and IL-lp in PBMCs and higher expression of these cytokines,. 
together with interferon (IFN)-y, in lymphoid tissues. Elevated levels of TNF-a 
and IL-6 are also found in plasma and cerebrospinal fluid [42, 212]. 
Overproduction of these cytokines could Contribute to AIDS pathogenesis; in 
fact, IL-6 and TNF-a have been reported to induce HTV-l expression in infected 
cells by acting at the transcriptional or post-transcriptional level [102, 292] andv 
enhanced serum levels of IL-6 have been associated with the subsequent- 
development of B-cell lymphomas [291]. Furthermore, cytokine dysregulation 
in macrophages, glial cells and astrocytes has been found to strictly correlate' 
with neuronal dysfunction, brain injury and HTV dementia [149, 246, 266].
Recent discoveries in the field of HTV-l coreceptors have provided new 
information about factors affecting disease progression (see section 1.2.6).
1.1.2 The structure and genome of HIV-l
HTV-l is a member of the lentivirus genus of the Retroviridae family. The 
HTV-l virion (Figure 1.1) is a spherical particle with a 90-130 nm diameter and 
a dense core [142].
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Figure 1.1 Schematic representation of the HTV-l virion
The envelope of the virus consists of a lipid bilayer derived from the host cell 
membrane and two noncovalently associated subunits, gpl20 and gp41, 
generated by cleavage of the gpl60 precursor. The external gpl20 glycoprotein 
derives from the N-terminal portion of gpl60 and contains the CD4 binding 
site. gp41 is a transmembrane molecule derived from the C-terminal portion of 
gpl60 and contains at its N-terminus a hydrophobic fusion peptide thought to 
be responsible for fusing the viral and target cell membranes [399]. The viral 
envelope glycoprotein (Env) that spikes from the surface of the virion or of
infected cells is a trimeric structure containing three gpl20/gp41 complexes 
[385]. Most of the exposed surface of the assembled trimer is composed of 
elements of gpl20, with the gp41 ectodomain largely buried inside the complex. 
Together with virus-encoded proteins, host-encoded transmembrane proteins, 
such as p2-microglobulin and MHC class I and II proteins, remain trapped in 
the lipid bilayer upon virion formation [12].
• The viral genome consists of two identical copies of single-stranded 
RNA, each about 9.2 Kb long. Immediately after entry into cells, virion RNA is 
converted into double-stranded linear DNA that is subsequently integrated 
into the host cell genome as a provirus. The genome of HTV-l (Figure 1.2), like 
that of all retroviruses, contains two identical long terminal repeats (LTR), that 
flank the viral genes, and contain discrete enhancer elements that bound and 
are controlled by several host transcription factors [83, 353].
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Figure 1.2 Genomic organization of HIV-l
The 5' LTR contains enhancer and promoter sequences essential for proviral 
transcription, whereas the 3' LTR is required for transcript polyadenylation.
Like most retroviruses capable of replication, HTV-l contains three main 
genes (gag, pol and env). The env gene encodes the precursor glycoprotein
gpl60, which is cleaved into gpl20 and gp41. The viral core is encoded by gag 
and includes p24 (capsid), pl7 (matrix), p9 and p7 (nucleocapsid). The pol gene 
encodes the precursor for several virion enzymes, i.e., reverse transcriptase 
(RT), Rnase H, protease and integrase (IN) [118, 286]. Furthermore, the HIV-l 
genome contains six additional genes (tat, rev, vif, vpr, vpu/vpx  and nef) 
encoding viral proteins with regulatory or accessory functions [83, 365] (see 
below).
1.1.3 Replication cycle
The HTV replication cycle starts with the attachment and entry of the virus into 
target cells. HIV-l entry is mediated by a high affinity interaction between the 
envelope glycoprotein gp!20 and CD4 [85, 198]. In addition, gpl20 uses 
members of the chemokine receptor family (described in detail in section 1.2) 
as coreceptors for entry. These interactions induce in gpl20 a series of 
conformational changes [325] which trigger the exposure of the fusogenic 
portion of gp41. This in turn leads to pH-independent fusion between the 
virus and the host cell membranes [350, 385].
After fusion, the inner core of the virion is released into the cytoplasm 
and rapidly uncoated. The viral single-stranded RNA genome is converted 
into blunt-ended, double-stranded DNA by the enzyme RT. It is at this step that 
genetic variability appears, due to the errore-prone action of viral RT, which 
lacks proofreading ability. Viral DNA is thereafter transported into the nucleus 
as a preintegration complex which also contains the HTV-l matrix and Vpr 
proteins, that regulate this process [49,165]. At this point, integrase is required 
to integrate proviral DNA into the host genome. Integration of HTV-l, which 
occurs at random sites, seems to be essential for replication [319]. Non­
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integrated circular forms of viral DNA are in fact presumably non-functional, 
dead-end products of the replication cycle [47].
Integrated proviral DNA may remain silent until the host cell is 
activated. Cellular activation by mitogenic or non-mitogenic stimuli and 
cytokines recruits to the 5' LTR host transcription factors such as NFAT-1, USF, 
AP-1 and most importantly, NF-kB which - in combination with factors 
expressed under basal conditions (e.g., Spl and TFOD) - promote the full 
expression of HIV-1 genes [14, 139, 261]. LTR-driven gene expression can also be 
activated by proteins encoded by a variety of other viruses and retroviruses [23, 
144].
The mRNA species encoded by HTV-l can be divided into two classes 
based on their temporal expression. HIV-1 proviral transcription starts with 
the formation of multi-spliced RNA species (2 Kb) which encode the regulatory 
proteins Tat, Rev, and Nef [334] and represent the early class of mRNAs. Tat is 
a potent transactivator of HTV-l transcription that acts via an RNA structure 
termed TAR (transactivation responsive region), located immediately 3Z to the 
LTR transcription start site [89,124]. Tat increases the levels of viral transcripts 
and stabilizes the elongation of RNA transcripts that would be otherwise all 
prematurely terminated [82, 189]. Nef is required for efficient virus replication 
in primary lymphocytes and macrophages [90, 251, 348]. The late class of 
mRNAs consists of unspliced (9 Kb) and single spliced (4 Kb) transcripts 
encoding structural and accessory proteins [119, 194]. The expression of late 
mRNA species is dependent on the Rev protein. Rev binds to a complex RNA 
structure in the env gene, the RRE (Rev responsive element), and enables the 
nuclear export of unspliced and single spliced mRNA. Translation of the late 
transcripts by the cellular machinery gives rise to the HTV structural proteins.
The envelope precursor protein gpl60 is glycosylated post-translationally and 
oligomerises in the endoplasmic reticulum (ER) before being incorporated into 
virions budding at the plasma membrane. During this transport, gpl60 is 
cleaved into the gpl20 and gp41 subunits. The Vpu regulatory protein is 
thought to enhance this process, and to inhibit the ER trapping of envelope 
proteins that would result from CD4 degradation [218, 391]. The myristoylated 
Gag and Gag-Pol precursor proteins aggregate at the inner surface of the cell 
membrane forming a spherical structure in which two copies of single­
stranded RNA genome are encapsidated. The assembled core-RNA complex 
buds through the plasma membrane where it acquires the lipid layer, complete 
with viral envelope and host proteins [12, 142]. During this budding process, 
viral protease cleaves the Gag and Gag-Pol precursors into functional proteins, 
leading to the formation of a mature virion.
Among the HTV regulatory gene products, Vif is thought to play an 
essential role during virion maturation, since virions produced in the absence 
of Vif are less infectious [123, 320]. The Vpr protein is packaged into the virion 
nucleocapsid in molar amounts equivalent to those of Gag [69]. Vpr confers 
growth advantages to HTV-l isolates expressing the protein, particularly in 
non-dividing cells such as primary macrophages. The myristilated Nef protein 
may also induce specific down-regulation of surface CD4 and MHC class I 
expression via endocytosis and lysosomal degradation. Through these 
mechanisms, Nef could hamper additional HTV infection and facilitate virion 
release from cells that express high levels of CD4 and would therefore trap 
virions on the cell surface. In addition, Nef can protect infected primary cells 
against killing by CTLs [1,70].
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1.1.4 HIV-1 variability
Several factors influence the considerable genetic diversity of HTV-l that is one 
of its major characteristics. First, the error-prone nature of viral RT allows for 
nucleotide substitutions, deletions, insertions, duplications and 
recombinations. HTV-l recombination occurs when two retroviruses 
containing different RNA strands infect the same cell, and the RT enzyme 
switches template during proviral DNA synthesis. Variation is amplified by 
the high viral turnover rate. It has been estimated that the virus half-life could 
be as short as 6 hours and that approximately 1010 new virus particles are 
produced and cleared every day [2, 10, 175, 382]. Finally, selective pressure 
allows for the rapid emergence of drug-resistant and immune escape mutants. 
Thus, heterogeneity is not confined to isolates from different individuals, and 
these factors continually drive the emergence of new virus variants within 
individual patients, giving rise to a population of closely related viral variants, 
commonly referred to as a quasispecies [162, 248]. Most commonly, during 
primary HIV-1 infection patients harbour a homogeneous population of 
viruses. With time, the viral population becomes increasingly heterogeneous. 
At later stages of the disease, the virus quasispecies may again become more 
homogeneous probably because individuals showing CD4+ T cell decline and 
rapid progression to AIDS maintain a weaker immune response, resulting in a 
lower level of selection-driven changes in the virus pool [92, 153, 241, 411]. 
Compartmentalization of the quasispecies in different body organs has been 
documented in tissues such as brain, lung and testis, whereas lymphoid tissues 
usually harbour virus variants similar to those circulating in peripheral blood 
[375].
Genetic variation can arise throughout the HTV-l genome. However, 
sequence variation is particularly high within the env gene, which is 
subdivided into five variable regions designated V1-V5 and interspersed with 
five more conserved regions termed C1-C5 [349, 399]. Mutations in the Pol and 
Gag proteins more often result in non-viable viruses, while env proteins 
tolerate extensive variation, which may actually represent a strategy to escape 
host immune surveillance.
Genetic analysis of viral sequences, predominantly from env and gag, 
has revealed that HTV-l can be divided into three groups, major (M), outlier 
(O), and the recently found novel (N) [345]. Within the M group at least nine 
subtypes (A to H and J) have been identified [187, 260]. Inter-subtype variation 
has been shown to be approximately 20-30% for the env and 14% for the gag 
region, whereas the intra-subtype diversity is approximately 7-20% [136, 229]. 
Different subtypes exhibit different geographical distributions, but with the 
continuous spreading of HTV-l it is becoming increasingly difficult to draw 
sharp borders. Subtype B viruses predominate in the North American 
continent, Europe and Australia. Both subtypes B and F are prevalent in South 
America, where subtype C has also been reported. Subtype G, as well as subtype 
H, has been isolated in Russia. Subtype E predominates in South Est Asia, 
while all group M subtypes, as well as group O variants, are found in Central 
Africa [36,37, 136, 187, 388]. Cases of infection with two different strains of the 
same subtype, as well as two different subtypes (B and E) of HIV-1 have been 
reported. Moreover, chimeric viruses between two subtypes have been 
described.
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1.1.5 HIV-1 phenotypes
HTV-l genetic variation translates into a variation in biological 
properties, such as cell tropism, virulence and sensitivity to host im m une 
responses. HTV-l strains have been traditionally divided into two categories, 
based on their cellular tropism, replication kinetics, and ability to induce 
syncytia formation [56,121, 356]. Virtually all HTV-l strains replicate efficiently 
in CD4+ peripheral blood lymphocytes (PEL). Many primary isolates are also 
able to grow efficiently in macrophages but not in immortalized T cell lines, 
and are thus termed macrophage-tropic (M-tropic). Based on the virus 
replication rate and the capacity to induce syncytia formation in T-cell lines, M- 
tropic viruses are also referred to as slow/low or non syncytia inducing (NSI). 
By contrast, T-tropic, rapid/high or syncytia inducing (SI) strains grow in T-cell 
lines, fonn syncytia in MT-2 cells and PBMC and tend to show higher 
replication rates and cytopathicity in vitro. The ability of SI isolates to 
productively infect macrophages has been controversial for some time (see 
section 4.2). Indeed, while T-cell line-adapted (TCLA) strains usually fail to 
replicate in monocyte-derived macrophages (MDM) [269], conflicting results 
have been reported when primary isolates (unselected by passage in cell lines 
in vitro) were used [75, 303, 326, 344, 373, 404].
The different HTV-l phenotypes have been found to be strictly correlated 
with viral transmission and AIDS pathogenesis [74, 117, 156, 250]. Typically, 
upon transmission of HTV-l between individuals, the NSI/M-tropic strains 
selectively take hold in the recipient and predominate during the 
asymptomatic phase of HTV-l infection, which generally lasts for several years. 
SI/T-tropic strains are usually detected much later in many infected 
individuals, and their emergence is often associated with the rapid decline of
CD4+ T cells heralding the demise of the immune system and the onset of 
AIDS [56,121,333,357].
To map the viral determinants responsible for cell tropism, several 
laboratories analyzed chimeric molecular clones of T-tropic and M-tropic HIV- 
1 isolates [58,185,272,337,389]. The replication properties of these chimeras in 
different target cells led to the conclusion that the env gene (particularly a 
region of gpl20 that includes the V3 loop) determines T- versus M-tropism. 
Subsequent studies confirmed the critical role of the V3 loop in the cell 
tropism of HTV-l, although interactions with other regions of gpl20 (e.g. V1 
and V2) also appear to be important [193, 202, 361]. However, it was only with 
the identification of HTV coreceptors that the mechanisms underlying HTV-l 
cell tropism were fully unravelled.
1.2 CORECEPTORS FOR HIV-1 INFECTION
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It had been known since the mid-1980s that CD4, a receptor expressed on the 
surface of T helper cells and macrophages, is required for high affinity binding 
of HIV Env to target cells, and therefore represents the major receptor for the 
docking of HTV on the membrane [85, 198]. However, later studies showed that 
expression of human CD4 on murine cells is not sufficient for HTV-l infection 
[233]. Binding of gp!20 to CD4-transfected murine cells could be demonstrated, 
yet virus entry did not occur. This phenomenon was observed also for HTV-2 
and SIV and was shown not to be restricted to murine cells [63]. In fact, almost 
all non-human cells remain refractory to HTV-l infection even when induced 
to express human CD4. Notably, nonpermissive CD4+ cells can be made 
permissive for Env-mediated membrane fusion and infection by transient 
heterokaryon formation with HeLa cells, indicating that one or more 
components (or cofactors) in HeLa cells render non-human cells susceptible to 
HTV-l infection [46, 99].
These results implied that HTV needs one or more factors other than 
CD4 for efficient entry into human cells. These cell surface molecules must be 
widely expressed in human cells of different lineages because, with rare 
exceptions [57], expression of CD4 on a variety of human cell lines renders 
them susceptible to HTV infection.
1.2.1 Chemokine receptors, the HIV coreceptors
Over the last 4 years it has become clear that the coreceptors required for HIV to 
infect CD4+ cells are the chemokine receptors [5, 60, 93, 100, 120]. Central to this 
breakthrough were the findings of a study on the identity of soluble HIV
suppressive molecule(s) released by CD8+ T cells. During the initial phases of 
HIV infection, the host immune system has the ability to restrain, albeit 
incompletely, virus spreading throughout the body [280]. CD8+ T lymphocytes 
play an important role in controlling virus replication [329] and this im m une 
control is mediated, at least in part, by soluble HIV suppressive factors 
produced by activated CD8+ T cells [380]. The nature of such factors remained 
elusive for almost 10 years until Cocchi et al. reported the identification of 
three C-C chemokines - regulated upon activation, normal T cell expressed and 
secreted (RANTES), macrophage inflammatory protein (MlP)-la and MIP-lp - 
as major components of the HFV-suppressive activity released by both primary 
and in vitro immortalized CD8+T cells [67].
The experimental approach that lead to this discovery started with an 
analysis of the effect of supernatants from HTLV-I immortalized CD8+ cloned T 
cell lines on the acute infection of a CD4+ T cell line (PM1) with an M-tropic 
strain, HIV-lBa_L. Cell-free supernatants from clones with the highest HIV- 
suppressive activity were fractionated through a tangential flow filter and 
centrifugal concentrators. The concentrated fraction displaying HIV- 
suppressive activity in the PM1/ HIV-lBa.L test was further fractionated by weak 
anion-exchange high-performance liquid chromatography (HPLC). Fractions 
containing high levels of suppressive activity were pooled and further purified 
by reversed-phase HPLC. Potent HIV-suppressive activity, in the absence of 
significant cytotoxic effects, was recovered in separate fractions, each containing 
a single major protein peak. These proteins were each subjected to proteolytic 
digestion, followed by sequencing of distinct peptide fragments. The amino 
acid sequences revealed identity with three human C-C chemokines, RANTES, 
MIP-la, and MIP-lp. Importantly, the HIV-suppressive activity expressed by
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CD8+ cells was completely blocked by a combination of neutralizing antibodies 
against these chemokines. When used as recombinant molecules, the three 
chemokines were active both alone and in combination, and they did not affect 
the viability nor the proliferative capacity of target cells.
RANTES, MIP-la, and MIP-lp induced dose-dependent inhibition of the 
replication of different strains of primate lentiviruses (HIV-1, HIV-2, and SIV), 
whereas other RNA and DNA viruses, such as HTLV-I or hum an 
herpesviruses (HHV) 6 and 7, were not susceptible. Notably, chemokines were 
not equally effective against all viral strains: M-tropic/NSI HIV-1 isolates were 
potently inhibited, while T-tropic/SI isolates were insensitive.
The HIV suppressive activity of C-C chemokines strongly suggested that 
chemokine receptors might serve as coreceptors for HIV infection. This 
hypothesis was very soon confirmed by the identification of the CXC- 
chemokine receptor fusin (now designated CXCR4) as the coreceptor for the 
entry of T-tropic HTV-l strains into CD4+ cells. Feng et al. [120] devised a 
functional cDNA screening strategy to identify essential HTV coreceptors. 
Interestingly, this approach made no assumption about the nature of the 
cofactor(s) and was based on the ability of a cDNA library to render CD4- 
expressing murine cells permissive for fusion with cells expressing Env from a 
TCLA strain (HIV-l^g). By repeated cycles of analysis, a single cDNA was 
isolated capable of conferring fusion ability to CD4-expressing murine cells. 
cDNA sequence analysis indicated that cell fusion mediated by the H IV -l^ Env 
was dependent on the expression of CXCR4/fusin, a member of the seven- 
transmembrane domain family of receptors highly homologous to CXC- 
chemokine receptors. The role of fusin as an HIV-1 coreceptor was further 
documented by demonstrating that coexpression of fusin and CD4 rendered
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nonhuman cells permissive for Env-mediated cell fusion and infection, and 
anti-fusin antibodies potently inhibited fusion and infection of primary 
human CD4+ T lymphocytes. As shown in figure 1.3, the natural ligands for 
CXCR4, unknown at the time, were later shown to be stromal cell-derived 
factor (SDF-l)a and SDF-lp, which are generated by alternative splicing of a 
single gene [33, 273].
Figure 1.3 Chemokine receptors as coreceptors for HIV-1
The work by Feng et al. showed that CXCR4 is the coreceptor for 
TCLA/SI HIV-1 isolates. However, CXCR4 was unable to mediate fusion of M- 
tropic HIV-1 isolates, whereas CC chemokines (RANTES, MIP-la and MIP-lp) 
potently inhibited infection by M-tropic/NSI but not by TCLA/SI strains. This
HIV-1
SI/X4 DualtropicX4R5
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discrepancy set the stage for the discovery of the second major coreceptor for 
HIV. Five different groups [5, 60, 93, 98, 100] simultaneously identified CCR5, 
the only C-C chemokine receptor known to selectively bind RANTES, MIP-la 
and MIP-lp [323], as the main coreceptor for M-tropic HIV-1 isolates (figure 1.3). 
Similar to CXCR4, CCR5 was found to be essential for fusion between infected 
and uninfected cells; moreover, its expression induced susceptibility to HIV-1 
infection, as assessed by virus production [5] or reporter gene expression [60, 93, 
98]. CCR5 and CXCR4 are both expressed on known cell and tissue targets of 
HIV-1. In particular, CCR5 is expressed on monocytes, macrophages [72, 314], 
microglia, dendritic cells [157, 315], Langerhans cells [406], CD4+ T cells [34], and 
the mucosa of rectum, colon, vagina and cervix [279, 409]. CCR5 levels on T 
cells are upregulated by interleukin 2 [228]. CXCR4 is expressed on virtually all 
hemopoietic cells.
In addition to CCR5 and CXCR4, several other chemokine receptors or 
structurally related molecules (listed in Table 1.1) [372] have been characterized 
as supporting HIV-1 Env-mediated fusion or viral entry in vitro. However, 
CCR5 and CXCR4 appear to be the coreceptors most widely utilized because in 
in vitro experiments all viruses use one or both receptors for entry. By contrast, 
CCR2b, CCR3, CCR8 and CCR9, the orphan receptors APJ, V28, STRL33, GPR1 
and GPR15, and the human cytomegalovirus-encoded chemokine receptor 
homologue US28 function as coreceptors only for a limited number of viral 
strains [408, 410]. Moreover, it should be noted that in vitro studies on the role 
of different chemokine receptors in supporting HTV-l entry are mostly 
performed using human cell lines that are stably transfected with both CD4 and 
individual potential coreceptors and express high levels of both molecules.
21
Therefore, it is not clear to what extent results obtained in such systems can be 
extrapolated to in vivo infection.
Alternative coreceptors for HIV and SIV
Receptor Ligand Expression pattern HFV/SIV isolates REF.
CCR2b MCP-1, MCP-2, MCP-3, MCP-4 Monocytes, T cells, B cells HIV-1 4,98,127
CCR3 Eotaxin, MCP-4, MCP-3, 
RANTES
Eosinophils, Microglia, Th2 
cells HIV-1
5,24,60,98 
164, 313, 315 
316
CCR8 1-309 Monocytes, Thymocytes HIV-1, SIV 178
CCR9 TECK Activated PBMC, Thymus HIV-1 59
CX3CR1 (V28) Fractalkine/Neurotactin Lymphocytes, Brain, NK cells, 
Monocytes
HIV-1, HIV-2 306,316
APJ ? Brain; Spleen Hiv-i,srv 59,106
GPR1 ? Macrophages srv 111
BOB/GPR15 ? T cells. Colon SIV, HIV-2, 
HIV-1 94, 111
Bonzo/STRL33/
TYMSTR
CXCL16 T cells. Monocytes, Placenta SIV, HIV-2, 
HIV-1
94,224,227
US28 MIP-la, MIP-lp, RANTES, 
MCP-1
Monocytes, Lymphocytes in 
CMV-infected cells
HIV-1 290
Table 1.1 Chemokine receptor family members that function as receptors for 
HIV and SIV entry
Another relevant issue is the tissue expression pattern of potential coreceptors. 
Maintenance of high viral load is thought to require expression of coreceptors 
on activated CD4+ T cells [285], but firm evidence to this effect is still lacking for 
many of the putative coreceptors. A significant hindrance to further studies is 
the unavailability of specific chemokine ligands and/or neutralizing 
monoclonal antibodies for many of these molecules. Thus, in spite of the large 
number of potential HIV coreceptors identified by in vitro studies, only CCR5
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and CXCR4 have been established to play a major role in in vivo HIV 
infection.
Individuals homozygous for a 32 bp deletion in the CCR5 gene (ccr5 a32) 
which results in the lack of CCR5 expression, are resistant to HIV-1 infection 
(see section 1.2.6) [182,226,324]. The existence of these "natural knockouts" for 
CCR5 suggests that CCR5 plays a fundamental role during HIV-1 transmission 
and replication in vivo. The physiological importance of CXCR4, on the other 
hand, is documented by the finding that HIV-1 isolates obtained from patients 
who experience a dramatic drop in circulating CD4+ cells and rapid disease 
progression use this coreceptor efficiently in vitro [32, 76, 326, 344].
The expression and use of different coreceptors in cell types other than 
mature T lymphocytes and macrophages (e.g. cells in the brain or thymus) 
could contribute to some aspects of HIV-1 pathogenesis in both children and 
adults [26, 359]. Indeed, blockade of HIV-1 entry by the CCR3 ligand eotaxin 
indicated that CCR3 is an HIV coreceptor in microglia, although there is no 
consensus as to the relative importance of CCR3 and CCR5 for viral entry into 
these cells [26, 29,148].
1.2.2 Chemokines, the natural ligands for HIV coreceptors
The discovery that chemokine receptors were the long sought coreceptors for 
HFV-l infection resulted in a renewed interest in chemokines. These 
molecules represent a superfamily of 40 or more structurally related, low 
molecular weight (8- to 10-KDa) proteins that regulate migration and 
activation of mammalian leukocytes [17, 18]: hence their name, a contraction of 
chemotactic cytokines. Chemokines coordinate trafficking of different 
leukocyte subtypes to specific tissue destinations. Furthermore, they mediate
23
inflammatory responses by recruiting specific immune cells to the sites of 
inflammation, and inducing their activation [18].
Four classes of chemokines (CXC or a, CC or (3, C or y, and CX3C or S) can 
be defined based on the number and spacing of conserved cysteines. The CX3C 
and C groups include only one known member and were identified only 
recently [25, 192], whereas more than a dozen members have been identified 
for the CC and CXC groups. In humans, the genes encoding CXC and CC 
chemokines are located in two distinct clusters on the long arms of 
chromosome 4 and 17, respectively. CXC chemokines are generally active on 
monocytes, neutrophils and peripheral blood T lymphocytes, whereas CC 
chemokines attract basophils and eosinophils, lymphocytes and monocytes [18]. 
Recently, it has also become clear that chemokines can be broadly divided into 
two categories (see Table 1.2): inflammatory, which are induced or strongly 
upregulated in peripheral tissues upon inflammation; and constitutive, which 
are involved in baseline leukocyte trafficking [16].
Chemokines induce leukocyte chemotaxis by binding to specific seven 
transmembrane domain G protein-coupled receptors [259]. There is 
redundancy in the system, i.e., most if not all chemokine receptors recognize 
more than one chemokine ligand, but they tend to be restricted by chemokine 
class. Ten human receptors specific for CC chemokines (CCR1-10) and five 
human receptors for CXC chemokines (CXCR1-5) have been identified by 
molecular cloning. Only one member of the family, the Duffy antigen receptor, 
is able to bind both CC and CXC chemokines [87, 268]. XCR1 binds the C 
chemokine lymphotactin, and CX3CR1 binds the CX3C chemokine fractalkine 
or neurotactin (reviewed in [257]).
Inflammatory
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Constitutive
CCRl 
CCR2 
CCR3 
CCR5 
CCR6 
CXCR1 
CX CR2 
CX CR3
CCR4
CCR7
CXCR4
CXCR5
Table 1.2 Human chemokine receptor-ligand specificity. Chemokine receptors 
are grouped according to their specificity for inflammatory or constitutive 
chemokines (modified from Sallusto et al. Immunology Today 1998 19: 568- 
574).
The definition of the role of chemokines and chemokine receptors in 
HFV-l infection has had two implications of great conceptual and practical 
relevance. On the one hand, chemokines may prevent viral infection by 
competing with viral envelope proteins for chemokine receptor occupancy. In 
addition and most importantly, the identification of chemokine receptors as 
HIV coreceptors has provided a molecular basis for the different tropism of
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different HIV-1 strains, making it possible to associate viral phenotypes with 
specific coreceptor usage.
1.2.3 Chemokine receptors as determinants of viral tropism
For a long time, HIV-1 isolates were defined in terms of their cellular tropism 
(see also section 1.1.5). M-tropic/NSI viruses infect macrophages and primary T 
cells but not most immortalized T-cell lines. In contrast, T-tropic/SI viruses 
can infect primary T cells and T-cell lines, but their ability to infect 
macrophages has been controversial.
The molecular mechanisms underlying differences in both cellular 
tropism and phenotype among different strains of HFV-l became apparent with 
the discovery that human chemokine receptors act as coreceptors for virus 
entry into CD4+ cells (Figure 1.4). In particular CCR5, the RANTES, MIP-la and 
MIP-lp receptor, has been shown to serve as the main coreceptor for M- 
tropic/NSI viruses [5, 60, 93, 98, 100] whereas CXCR4, the natural receptor for 
SDF-1 [33, 273], mediates the entry of SI HIV-1 strains, both primary and TCLA 
[120]. According to the most recent nomenclature based on receptor tropism, 
CCR5-tropic viruses are defined as R5, CXCR4-tropic viruses as X4, and dual­
tropic viruses as R5X4 [27]. Studies of the expression of these receptors revealed 
that most T cell lines express high levels of CXCR4 and only rarely CCR5 [396]. 
However, while the lack of CCR5 expression on most T-cell lines provided a 
rationale for the inability of NSI strains to infect these cells, the ability of HIV-1 
strains with an SI phenotype to infect macrophages was not clearly established. 
This issue is addressed in the Results (section 4.2) and in the Discussion 
(section 5.2).
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T-Tropic 
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M-Tropic
Slow-Low
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Mononuclear CD4 + T Lymphocytes CD4 + T-Cell Lines
phagocytes
Figure 1.4 Biological variants of HIV-1 and their tropism
1.2.4 Interactions between HIV, CD4 and the coreceptors
Biochemical studies using recombinant gpl20z soluble CD4 and human or 
mouse cell lines transfected with chemokine receptors have addressed the 
interactions of gpl20 molecules from R5 or X4 isolates with their specific 
coreceptors. Radiolabeled gpl20 from R5 isolates binds CCR5-expressing cells 
only in the presence of added soluble CD4 [395]. HIV-1 and SIV envelope 
glycoproteins are able to compete with RANTES, MIP-la and MIP-lp for CCR5 
binding [172, 364,395]. This competition was shown to be much more efficient 
in the presence of CD4, either co-expressed with CCR5 on the cell surface, or 
present in soluble form as a preformed complex with gp!20. By contrast, 
soluble gp!20 from X4 strains was found to form a precipitable complex with
CXCR4 [214], and to specifically bind CXCR4-expressing cells even in the 
absence of surface-bound or soluble CD4 [171]. However, the affinity of such 
interaction was clearly lower than that of the sCD4-HIV Env complex for 
CXCR4 [21]. Moreover, it has been shown that the association between CXCR4 
and CD4 is enhanced in the presence of gpl20, although it occurs to some 
extent also in its absence [369]. These findings suggest that the initial 
interaction of HIV-1 strains with CD4 induces a conformational change in 
gp!20 which exposes, creates or stabilizes the subsequent binding of the 
envelope to the coreceptor. The binding of coreceptors to gpl20 would trigger 
further conformational changes in the HFV-l envelope, leading to exposure of 
regions of gp4l that mediate direct interactions with the lipid layer of the target 
cell membrane.
Recent papers have investigated determinants on gpl20 responsible for 
tropism, Env-coreceptor interactions and fusion events. Results from these 
studies indicate that the V3 loop is critical for gpl20 binding to coreceptor but, 
during the fusion process, V3 works in concert with other gpl20 regions, 
including VI, V2 and C4 [209, 309, 398].
There are rare examples of situations in which CD4 is not even required 
for primate immunodeficiency lentiviral entry. This phenomenon was first
described for HIV-2 strains that were selected for growth in CD4 cells and
utilize either CXCR4, CCR5, CCR3 or the orphan receptor V28 [108, 305-307]. 
The same phenomenon was then observed for SIV [107, 237] and HFV-l [103, 
305]. Indeed, primary human fetal astrocytes, negative for CD4 and the major 
HFV-l coreceptors CCR5, CXCR4, CCR3 and CCR2b, can be infected in vitro 
with HIV-1 isolates independently of coreceptor usage [318].
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1.2.5 Structure-function studies on HIV coreceptors
All of the identified HIV/SIV coreceptors are members of the seven 
transmembrane domain G protein-coupled receptor family. As such, they 
contain an N-terminal extracellular domain, that is acidic and tyrosine-rich, 
and three extracellular loops (ECL 1-3) (Figure 1.5).
A' ÜY, y
Cytoplasm
Figure 1.5 Schematic representation of a chemokine receptor
Although they share a common structure, HIV coreceptors show 
marked variation at the amino acid level. Thus, structure-function studies 
have been performed to determine the region(s) needed by a seven- 
transmembrane-domain chemokine receptor to be a functional HIV 
coreceptor, and the amino acid residues that interact with the viral envelope. 
In addition, these studies have investigated whether the biological functions of 
G protein-coupled receptors (such as signaling and internalization) are 
required for HIV entry and infection.
Chimeric, mutant, and non-human homologous coreceptors have been 
constructed to identify the molecular determinants of CCR5 and CXCR4 
coreceptor function. Structure-function studies of CCR5 suggest that multiple 
extracellular domains are involved in the activity of this coreceptor. 
Experiments performed on human/murine CCR5 chimeras showed that each 
of the extracellular domains of human CCR5 is independently capable of 
conferring some degree of coreceptor function to an otherwise inactive murine 
receptor [13, 30, 207, 287]. Notably, these chimeric coreceptors are often 
functional for a significantly more restricted range of HIV-1 strains, implying 
that different strains can interact with the coreceptors in different ways. Within 
this context, dual-tropic isolates appear to be particularly sensitive to 
perturbations in the human CCR5 extracellular regions [95, 302]. Functional 
redundance of the extracellular sites of CCR5 was also observed by studies on 
CCR5/CCR1, CCR5/CCR2b, CCR5/CXCR2 and CCR5/CXCR4 chimeras [97, 105, 
230, 317]. Furthermore, mutational analysis of the extracellular domains 
consistently showed that residues important for coreceptor function are 
scattered throughout these regions, although several important residues are 
clustered within the N-terminus and ECL-2 [97, 101, 113, 302]. Of note, CCR5 is 
posttranslationally modified by sulfation of its N-terminal tyrosines. Sulfated 
tyrosines contribute to the binding of CCR5 to MIP-la, MIP-lp and HIV-1 
gp!20/CD4 complexes and to the ability of HFV-l to enter cells expressing CCR5 
and CD4 [114].
Similar approaches to analyse structure-function relationships in CXCR4 
led to the conclusion that multiple domains are involved in coreceptor 
activity. Unlike CCR5, the N-terminal domain of CXCR4 is considerably less 
important while ECL-1 and, particularly, ECL-2 appear to be critical for
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coreceptor function [43, 230, 304]. These domains are also involved in SDF-1 
binding, which could explain how this chemokine suppresses HIV infection.
Glycosylation could potentially modulate coreceptor utilization by 
creating and/or covering Env binding sites. CXCR4 has two potential N-linked 
glycosylation sites, one in the N-terminal domain and one in ECL-2, while 
CCR5 has one potential site in ECL-3. However mutation or elimination of 
these sites in both coreceptors has shown that they are not required for 
coreceptor function [43, 288, 317].
Activation of chemokine receptors by binding of their natural ligands 
leads to G protein coupling and subsequent intracellular signaling (reviewed in 
[298]). Therefore, during HIV infection binding of Env proteins to chemokine 
receptors could potentially initiate a signaling cascade affecting entry or post­
entry events. To address this issue, conserved domains in the cytoplasmic 
region of CCR5 have been modified to prevent CCR5-mediated signaling [9, 
112, 154]. Several studies indicate that signaling is fully dissociable from the 
role of CCR5 as an HIV coreceptor. Similar findings have been reported for 
CXCR4 [181, 230]. In addition, overexpression of arrestin (which enhances 
chemokine receptor internalization) or dominant negative arrestin mutants 
(which block chemokine-induced internalization) had no effect on the ability 
of CCR5 to act as an HIV coreceptor [9]. However, while signaling is not 
required for the entry of HFV-l into target cells, it might be necessary for post­
entry steps of the viral life cycle. Interestingly, monomeric or oligomeric gp!20 
molecules derived from several, but not all, M-tropic isolates could induce 
CCR5-mediated Ca2+ mobilization and chemotaxis in a proportion of activated 
CD4+ T lymphocytes [387]. Moreover, gp!20 molecules from various T-tropic or 
M-tropic isolates induce increased tyrosine phosphorylation of Pyk2 mediated
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by an interaction with CXCR4 or CCR5 [88]. Finally, gpl20 has been recently 
shown to specifically antagonize CXCR4 and CCR5 signaling in response to 
chemokines in a CD4-dependent fashion [232, 381]. These last results suggest 
that gpl20 shed from virions and infected cells may bind to uninfected CD4+ 
cells and affect the immune and inflammatory responses of infected 
individuals, thus contributing to the immunosuppressive effects of HIV-1.
1.2.6 Chemokine receptors in viral transmission and disease 
progression
The identification of chemokine receptors that function as coreceptors for HIV- 
1 entry into target cells lead to reconsider several open questions related to 
HIV-1 transmission and disease progression. As shown in Figure 1.6, 
examination of the phenotypes of HFV-l strains sampled at different times 
during the course of infection revealed that recently infected individuals 
predominantly harbour R5 isolates, implicating the latter in viral transmission 
[81, 204, 374, 408]. Therefore, a major unanswered question is why X4 strains are 
rarely, if ever, transmitted, even though CXCR4 and other potential 
coreceptors are expressed on target cells, and X4 variants are present in the 
transmitting source. Indeed, X4 and R5/X4 isolates usually arise only late 
during infection and are prevalent during progression to symptomatic disease 
[32, 76, 326, 344]. However, it is not clear whether the emergence of CXCR4- 
dependent viruses is a consequence or rather the cause of the increasing 
immunosuppression, and what is the relationship between coreceptor usage 
and depletion of CD4+ T cells. As shown in figure 1.6, a rapid decline in T-cell 
counts is temporally associated with a switch from R5 to X4 or R5/X4 variants. 
Experimental infection with R5 isolates causes less T-cell depletion than
infection with X4 or R5/X4 variants in T cell cultures, ex vivo infected 
lymphoid tissue [150, 283, 332], and SCID/hu mice chimeras [289], despite 
similar levels of viral replication. Interestingly, a recent paper demonstrated 
that R5 isolates are highly cytopathic, but only for CCR5+/CD4+ T cells [160]. 
Because these cells represent only a small fraction of CD4+ T cells, their 
depletion does not substantially affect total CD4+ T cell counts.
X 4 /R 5 X 4 H IV
iov
D
U
Transmission AIDS
o
H-l
5
>
Time (years)
Figure 1.6 Temporal evolution o f HIV-1 coreceptor usage during HIV-1 
infection
Because of important clinical and pathogenetic implications, it is essential 
to understand why some individuals who have been repeatedly exposed to 
HTV through high-risk sexual contacts with infected subjects remain 
uninfected, and why a small minority of infected persons are LTNP. The 
fundamental role of CCR5 during HTV-l transmission in v ivo  is well
33
supported by the finding that some exposed uninfected (EU) individuals are 
homozygous for a 32 bp deletion in the coding region of the CCR5 gene [226]. 
Notably, lymphocytes and macrophages isolated from these individuals were 
resistant to infection with R5 strains but readily infectable with X4 viruses [75, 
281, 303]. The CCR5 sequence mutated in EU individuals encodes a region in 
the second ECL of the protein. The deletion results in a frame shift generating a 
severely truncated CCR5 protein which is not expressed on the cellular surface 
and rapidly degraded [91, 226, 324, 412]. About 20% of Caucasians are
heterozygous, and 1% are homozygous for the A32 allele. In contrast, the latter
was not observed in black African or Asian populations [225, 238]. Individuals
homozygous for the A32 allele exhibit a normal immunological profile but are
significantly protected against HIV-1 infection [91, 182, 324]. The A32/A32
genotype was found to be more frequent in several EU cohorts, including 
individuals exposed via mucosal or parenteral routes (homosexual men, 
intravenous drug users, and hemophiliacs). Indeed, only four individuals out
of several thousand examined have been shown to be both A32 homozygous
and HIV infected [20, 31, 271, 358]. In all cases, disease was progressive and the 
viral isolates appeared to be SI. In one of these individuals, X4 virus was 
exclusively and persistently detected [249].
Individuals heterozygous for the A32 allele are not highly resistant to 
infection [91,104, 182, 324, 412]. However, the heterozygous genotype seems to 
confer a marginal benefit to individuals who become infected, as indicated by 
lower viral loads, slower rates of CD4+ T-cell depletion, and increased times 
between seroconversion and progression to AIDS [247, 253]. All these 
observations suggest that during the initial phases of infection CCR5 is largely
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responsible for HIV-1 transmission both between individuals and within the 
same individual, but the underlying mechanisms remain unclear. A crucial 
point is the expression pattern of different coreceptors on cells targeted by the 
initial infection (monocyte/macrophages, dendritic cells, Langerhans cells, 
vagina, cervix, rectum and colon). In this context, CXCR4 appear to be 
expressed at lower levels than CCR5 in colonic and cervical mucosa [279, 409].
Another issue under intense investigation is why viruses that use 
CXCR4 tend to arise only late in the course of infection, and what is their 
association with the dramatic drop in CD4+ T cell counts. It has been proposed 
that the evolutionary pressures that may select for a shift in chemokine 
receptor utilisation could involve expression of inhibitory chemokines [366], 
depletion of specific target cells and/or escape from immune responses. In fact, 
the potential for using multiple members of the chemokine coreceptor family 
for cell entry may provide a convenient strategy for the virus to escape a potent 
neutralising host antibody response directed against regions (such as the V3 
loop) involved in specific interactions with receptors. Moreover, it has been 
hypothesized that CXCR4-dependent viruses become prevalent late in disease 
as a consequence of the selective depletion of CD4+ memory T cells, the subset 
that preferentially expresses CCR5. These are replaced at high rate by naive T 
cells which express preferentially CXCR4 [34], thus providing a selective 
advantage for X4 isolates. However, it is important to mention that the 
occurrence of SI/X4 isolates in only about 50% of patients with advanced 
disease indicates that the ability of the virus to use CXCR4 is not an absolute 
prerequisite for the onset and progression of AIDS.
LTNP are patients who, although infected, show no disease symptoms 
for 10-15 years or longer. Some of them appear to have been infected with
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highly attenuated viral strains, such as those bearing deletions in nef. 
However, the majority of LTNP appear to be infected with isolates that bear no 
obvious genetic defects. In these cases, it has been suggested that a peculiar 
genetic background of the individuals may underlie their relative resistance to 
disease progression. Recently, some polymorphisms have been identified in 
coreceptor and/or chemokine genes, and correlated with delayed HIV-1 disease 
progression:
• A heterozygous mutation in CCR2b [346] has been shown to correlate with
delay in the onset of disease. The protective effect of a single amino acid change 
(V64I) in the first transmembrane domain of CCR2b is unexpected because 
most HIV-1 strains are unable to use CCR2b as a coreceptor. However, the 
CCR2b polymorphism appears to be invariably associated with a 
polymorphism in the closely linked CCR5 promoter, the functional impact of 
which remains to be demonstrated. CCR2-64I has no effect on initial HIV 
transmission. However seroconvertors bearing the CCR2-64I allele tend to 
progress to AIDS 2-3 years later than CCR2 +/+ HIV seroconvertors. Moreover 
CCR2-64I is enriched among LTNP and reduced in rapid progressors [206, 308, 
346].
• A single nucleotide polymorphism in the CCR5 promoter (CCR5 59029 G/A) 
is associated with a 3-4 year delay in mean progression time to AIDS [239].
• Consistent with the critical importance of chemokines in HIV-1
pathogenesis, homozygosity for a polymorphism in the 3' untranslated region 
of SDF-1 (SDF1-3'A), the CXCR4 ligand, confers long-term protection against 
disease progression [393]. However, a clear role of SDF1-3'A in HTV-l disease 
has not been documented because a similar study on a different cohort
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reported that this polymorphism was actually associated with accelerated 
disease progression [255].
1.2.7 The therapeutic potential of chemokines and chemokine 
receptors
The identification of chemokine receptors that mediate HIV entry has obvious 
therapeutic implications. Indeed, chemokines are natural inhibitors of HIV 
entry. In particular, NSI/R5 viruses are inhibited by CCR5 ligands, such as 
RANTES, MIP-la and MIP-lp [67], and SDF-1 inhibits entry of SI/X4 or dual­
tropic HIV-1 viruses that use CXCR4 [33, 273]. Likewise, infection by NSI 
viruses that use CCR3 as a coreceptor is inhibited by eotaxin, the main CCR3 
ligand [164], and 1-309 inhibits CCR8-dependent infection by different HIV-1 
strains [178]. In addition, C-C chemokine homologues encoded by Kaposi's 
sarcoma-associated herpesvirus have been reported to block HIV infection [40, 
199].
Although the use of chemokines as anti-viral drugs may be complicated 
by their normal biological activity, these results have opened the way for a
number of novel antiviral approaches. Individuals homozygous for the A32 
allele in the CCR5 gene exhibit a normal immunological profile, [226, 324], 
suggesting that antagonists targeted specifically to this coreceptor would not 
have undesirable effects. The search for specific chemokine receptor 
antagonists is ongoing and involves the design of protein antagonists and 
peptide inhibitors. A number of studies have demonstrated that N-terminal 
modification and truncation of chemokines gives rise to specific receptor 
antagonists. This approach has been used to create two RANTES antagonists 
that display a potent inhibitory effect during infection with R5 strains in both
macrophages and lymphocytes [11, 231, 341]. Both proteins are N-terminally 
modified, have a high affinity for CCR5, lack chemoattractant activity and 
block RANTES-induced chemotaxis. By contrast, the design of CXCR4-targeted 
antagonists has to take into account the evidence that SDF-1 knock-out mice 
have lethal defects in B cell lymphopoiesis [262]. Nevertheless, it may be 
possible to develop small inhibitors that block viral interactions with CXCR4 
without compromising SDF-1 signal transduction. Two reports have described 
peptide inhibitors of CXCR4 that block HIV-1 infection [96, 256]. The first, 
known as T22, is an 18-residue oligopeptide, the second, known as ALX40-4C, is 
a highly cationic oligopeptide containing nine Arg residues. Both molecules 
specifically inhibited CXCR4-mediated membrane fusion and viral entry by X4 
isolates. In addition, ALX40-4C blocks SDF-l-dependent activation of calcium 
mobilization and binding of the CXCR4-specific monoclonal antibody 12G5. 
However, the therapeutic potential of these peptides is somewhat limited by 
their relatively poor metabolic stability. Recently, AMD3100 a heterocyclic 
bicyclam compound previously reported to block HIV-1 replication, was shown 
to inhibit binding of SDF-1 and 12G5 antibody to CXCR4, and to neutralize 
CXCR4-dependent viral infection [331]. However, all these compounds also 
block signaling through CXCR4 and it is not known whether they will have 
adverse effects on the host.
Chemokines exert two types of anti-HIV activities, competition for HIV- 
1 binding to chemokine receptors and downregulation of surface coreceptor 
expression. These processes are functionally linked since occupancy of the 
receptor triggers its internalization [6, 7, 231]. Thus, a reduction in the level of 
surface expression of viral coreceptors could represent an alternative strategy to 
inhibit HIV infection. To obtain cell-surface receptor depletion one group has
devised a mechanism to trap CXCR4 and CCR5 in the ER, thereby preventing 
their transport to the cell membrane [54, 400]. The tetrapeptide sequence KDEL, 
which is an ER retrieval sequence, was engineered onto the C-terminal end of 
MIP-la, RANTES and SDF-1. These intracellularly retained chemokines - 
called "intrakines" - can be transduced into lymphocytes where they prevent 
surface expression of newly synthesized CCR5 and CXCR4, probably by forming 
intracellular complexes. Gene therapy approaches have also been proposed to 
target CCR5 mRNA using ribozymes or antisense oligonucleotides [151]. 
Finally, fusion-competent HIV vaccine immunogens were generated that 
capture the transient envelope-CD4-coreceptor structures that arise during HIV 
binding and fusion. In a transgenic mouse immunization model, these 
formaldehyde-fixed whole cell vaccines elicited antibodies capable of 
neutralizing infectivity of 23 out of 24 primary HIV isolates from diverse 
geographic locations and subtypes A to E [211].
An important consideration in the development of therapeutic 
strategies based on coreceptor usage is the possibility that inhibitors of 
individual coreceptors could select for strains that use an alternative coreceptor 
or different regions of the same coreceptor. In this respect, it is even possible 
that CCR5-targeted therapy may accelerate the course of the disease by selecting 
for viral strains that use CXCR4 [196] or perhaps CCR2b, or CCR3, the 
emergence of which is associated with disease progression [76, 326]. These 
observations warrant the conclusion that a combination of agents aimed at 
abolishing the coreceptor function of both CCR5 and CXCR4 may be needed to 
successfully affect the propagation of HIV-1 in vivo.
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1.3 HIV-1 INFECTION IN HUMAN MACROPHAGES
HIV-1 infection requires access to host cells that are susceptible to and capable 
of replicating the virus. As emphasized above, cellular susceptibility is 
dependent upon membrane expression of CD4 and the chemokine receptors, 
mostly CCR5 and CXCR4. Thus the major cell lineages that are susceptible to 
infection in vivo are CD4+ T lymphocytes and monocytes/ macrophages. 
Macrophages play an important role in HIV transmission and propagation of 
viral infection. Macrophages can be found in the lamina propria adjacent to 
mucosal epithelium, and in cases of genital ulceration or lesion in the mucosal 
epithelium, they may come in direct contact with HIV [270, 296]. Thus, 
macrophages represent the predominant cell type infected with HIV in tissues 
[147, 201, 321]. HIV-infected macrophages are found in brain, lung, lymph 
nodes, and skin of seropositive patients and are likely to directly contribute to 
HIV-induced immunosuppression, central nervous system dysfunction and 
development of pulmonary complications. Indeed, HIV-2/SIVSM variants that 
infect macrophages inefficiently in vitro were considerably impaired in their 
replication capacity and pathogenicity in vivo [174].
Circulating monocytes show low levels of infection as assessed by DNA 
polymerase chain reaction (PCR), indicating that infection may occur after the 
cells have left the circulation and differentiated into macrophages [330]. In in 
vitro infections, macrophages are relatively resistant to the cytopathic effects of 
HIV-1. This observation led to the suggestion that infected macrophages may 
represent a major reservoir for the virus in vivo, contributing to the spread of 
virus to different tissues within infected patients and between individuals. 
Macrophages play also an important role in the presentation of antigens to
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CD4+ T cells, and it is possible that infected macrophages may transmit the 
infection to CD4+ T cells during this process [234].
In addition, macrophages modulate immune responses and tissue 
functions through the release of a large array of secretory molecules [267]. 
Changes in the secretion of cytokines and mediators occur during HIV 
infection and underlie the symptomatology of AIDS [116, 117, 347].
1.3.1 The viral cycle in macrophages
The HIV-1 life cycle in macrophages differs in many respects from that in T 
cells. Indeed, macrophages are terminally differentiated cells and, under 
normal conditions, they do not proliferate. Although retroviruses tipically 
infect only dividing cells [222], the action of several primate lentiviral proteins 
allows for efficient infection of nondividing macrophages. Thus, unlike T cells, 
a productive HIV-1 infection in these cells occurs independently of cellular 
DNA synthesis [141, 383].
Infection of susceptible macrophages can be mediated by CD4 and 
chemokine receptors, as well as by an alternative route. The observation that 
in vitro infection of macrophages with HIV was markedly enhanced (5- to 10- 
fold increase in RT activity) by sera from certain HIV-infected patients [310] 
suggested that virus-antibody complexes might bind to Fc receptors on the 
surface of macrophages and subsequently enter the cells via endocytosis. This 
mechanism, known as antibody-dependent enhancement (ADE), occurs in 
several human and animal viral diseases, including those caused by 
lentiviruses [52, 265]. It has been shown that ADE of HIV infection in 
macrophages is mediated by FcyRIII (CD16) in a CD4-independent fashion [176, 
363].
Analysis of HIV-infected macrophages by transmission electron 
microscopy suggests another fundamental difference between virus- 
macrophage and virus-T cell interactions. In HIV-infected lymphocytes, the 
assembly and budding of viral particles takes place on the cytoplasmic 
membrane. By contrast, few or no virions are found at the plasma membrane 
in macrophages. Yet these infected cells contain large numbers of viral particles 
which are localized almost exclusively in intracellular vacuoles that probably 
belong to the Golgi apparatus [35, 276].
Distinct effects of HIV-1 accessory genes were also observed in primary 
macrophages and lymphocytes. Mutational analysis of primary HIV-1 isolates 
showed that mutant viruses had markedly different patterns of replication in 
macrophages, whereas differences were modest in lymphocytes. Indeed, loss of 
Vpr or Vpu reduced viral antigen production in macrophages as much as 1000- 
fold, while replication in T cells was only marginally affected [19, 73]. Current 
consensus suggests that HIV-1 Vpr is a positive regulator of viral replication in 
macrophages. Most retroviruses fail to infect nondividing cells, as mitosis and 
conceivably the disintegration of nuclear membrane that occurs during cell 
division are prerequisites to their gaining access to the cell nucleus. However, 
in HIV-1, Vpr and at least two other virion proteins (matrix pl7 and IN) 
contribute to the nuclear import of proviral DNA in growth-arrested cells, 
such as macrophages [48, 131-133, 165]. The efficient translocation of proviral 
DNA into the cell nucleus is an active process driven by the interaction 
between an array of nuclear localization signals (NTS) present on matrix 
protein, IN, and Vpr and the cellular NLS receptor Karyopherin alpha [378]. In 
addition, Vpr has been reported to increase viral transcription in macrophages 
[354]; thus, the role of Vpr appears to be essential rather than accessory in this
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cell population, as it combines the ability to confer optimal infectivity (early 
function) with the ability to augment viral production after infection (late 
function).
After HIV enters the host cell and proviral DNA becomes integrated into 
the host genome, transcription of viral RNA is dependent on cellular proteins. 
Some cellular transcription factors required for HIV-1 transcription, such as 
Spl and NF-kB, are ubiquitously expressed while others, such as GATA-3, ETS- 
1, LEF-1, and NF-ATc are lymphoid- or T cell-specific [159, 195, 336, 402]. Recent 
studies demonstrate that there are three C/EBP binding sites within the HIV-1 
LTR and that C/EBP proteins are necessary for HIV-1 replication in 
macrophages but not in T cells [166-168]. C/EBPp is usually induced upon 
activation of macrophages and activates transcription of many endogenous 
genes whose products are important for monocyte /  macrophage function 
including the cytokines IL-lp, IE-6 , IE-8 , granulocyte-colony stimulating factor, 
and the chemokine MIP-la. Thus HIV-1 takes advantage of the mechanism 
used by monocyte/macrophages to coordinate the transcription of highly 
expressed endogenous genes. In addition, many of the cytokines produced by 
macrophages can further upregulate viral replication by inducing NF-kB and 
C/EBPp, and these 2 factors can interact synergistically. Thus, C/EBPp plays a 
central role in an autostimulatory pathway involving macrophages, cytokines 
and HIV-1 infection.
1.3.2 Role of macrophages in the pathogenesis of HIV-1 infection
Evidence from different lines of work highlights the deleterious role played by 
macrophages in HIV-1 disease. Unlike HIV-infected T cells, HIV-infected 
macrophages appear to be resistant to the cytopathic effects of the virus and
thus serve as a reservoir for persistent infection and virus dissemination. 
Furthermore, macrophages may serve as sites for virus replication late in AIDS 
when T cell numbers are low, or following withdrawal of treatment with viral 
inhibitors [53, 115, 141, 175, 284, 285]. In fact, the presence in the body of 
persistently infected macrophages represents a key challenge for therapeutic 
efforts to eradicate HIV infection by eliminating all cells harboring the viral 
genome and/or sustaining virus replication for a long period of time. Nerve 
growth factor (NGF) has been recently reported to be an autocrine survival 
factor that rescues human macrophages from the cytopathic effects of HIV 
infection [138]. Thus macrophages in spleen, lymph nodes, bone marrow, liver, 
and other tissues may take advantage of their autocrine NGF, survive and 
continuously produce viral particles. This may be particularly relevant in the 
central nervous system, where macrophages represent the majority of HIV- 
infected cells, and most resident cells are able to produce NGF.
HIV-1 infection of human macrophages is associated with increased 
apoptosis of CD8+ T lymphocytes. These cells are known to play an important 
role in the control of infection through their cytotoxic activity and the release 
of soluble HIV suppressive factors. In AIDS patients, the absolute number of 
CD8+ T cells is decreased in peripheral blood and their turnover rate is 
increased. Apoptosis in this cell population seems to be triggered by the 
interaction between TNF-a on the membrane of macrophages and TNF- 
receptor 2 expressed on CD8+ T cells. This phenomenon is indirectly mediated 
by the engagement of CXCR4 that upregulates cell surface expression of both 
molecules specifically in those cell subsets [170].
Another contribution of macrophage lineage cells to virus replication 
and pathogenicity resides in the ability of the accessory gene product Nef to
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induce production of C-C chemokines, particularly MIP-la and MIP-lp, by HIV- 
1-infected macrophages. Secretion of these chemokines promotes chemotaxis 
of resting T cells (which are normally refractory to productive infection) to sites 
of virus production, thus facilitating virus dissemination from infected 
macrophages to T lymphocytes [355].
Finally, one of the most important involvements of macrophages in 
HIV pathogenesis is associated with the emergence of opportunistic infections 
(OIs). The ability of HIV to infect and disable T cells renders the host susceptible 
to a broad range of opportunistic viral, bacterial, fungal, and protozoal 
pathogens that mark the progression of HIV disease. Infection with common 
opportunistic pathogens, such as HHV-1, Mycobacterium avium  complex, and 
Mycobacterium tuberculosis, is accompanied by increases in HTV-l viremia 
[146, 152, 169, 362]. Conversely, therapeutic intervention for treatment and 
prevention of a wide variety of OIs reduces viremia and consequently 
morbidity and mortality in AIDS. Analysis of lymphoid tissues co-infected 
with HIV-1 and OIs revealed that cells of the monocyte/macrophage lineage 
become the major source of the dramatic increase observed in HTV-l levels. 
Remarkably, pathogens have the capacity to establish foci of HIV production by 
recruiting HIV-l-infected and infectable macrophages and stimulating their 
viral expression [275].
1.3.3 Macrophages and bacterial infections
Besides their important role in both the natural history and the pathogenesis 
of HIV infection, monocyte / macrophages are critically involved in the 
response to bacterial infections. Lipopolysaccharide (LPS)/ endotoxin, the major 
constituent of the Gram-negative bacterial cell wall, activates multiple
macrophage effector functions that serve to coordinate host protective 
immune and inflammatory responses. However, increased exposure to LPS 
can lead to septic shock, a serious syndrome characterized by tissue injury, 
circulatory collapse, multiorgan failure, and death [39, 352]. LPS stimulates host 
cells, particularly monocytes and macrophages, to produce and release 
endogenous mediators including the proinflammatory cytokines IL-1, IL-6 , and 
TNF [371]. The effects of LPS are mediated by CD14, a 
glycosylphosphatidylinositol (GPI)-anchored membrane protein specifically 
expressed on cells of monocyte/ macrophage lineage [215, 394], and Toll-like 
receptor (TLR) 2 [197, 401] and TLR4 [295, 301] that act as signal transducers. 
Interestingly, CD14 serves as a recognition molecule for a wide variety of 
bacterial wall molecules, such as mycobacterial lipoarabinomannan (LAM) and 
components of Gram-positive bacteria [299]. Thus, CD14 is a pattern 
recognition receptor with multiple microbial ligand-binding specificities and 
for this reason belongs to the set of nonclonal immune receptors highly 
conserved throughout evolution, and responsible for nonadaptive (innate) 
immunity [242].
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2 Aims of the thesis
Macrophages play a key role in HIV-1 infection. On the one hand, these cells 
are essential for the pathogenesis of HIV-1 disease because they are among the 
first targets infected by the virus in vivo, and represent a major reservoir for 
HIV-1 at all stages of infection. Furthermore, unlike T cells, macrophages are 
resistant to the cytopathic effects of HIV-1. Infected macrophages may therefore 
persist in tissues for long periods of time, providing a vector for the spreading 
of infection to different tissues. In addition macrophages are thought to play a 
regulatory role in controlling disease progression through the release of 
inflammatory cytokines.
On the other hand, macrophages are critically involved in the im m une 
response to bacterial infections. LPS or LAM released by bacteria or 
mycobacteria evoke strong inflammatory responses by inducing macrophages 
to secrete cytokines and chemokines. This process is mediated by the 
engagement of CD14, a pattern recognition receptor for foreign lipoglycans 
expressed at high levels on monocytes and macrophages.
Patients with HIV-1 infection are immunosuppressed, often severely, 
and thus become highly susceptible to bacterial superinfections. Indeed, LPS 
can reach significant levels in the blood and liver of these patients. Therefore it 
was important to determine whether and how bacterial products modulate 
HTV-l replication. Interestingly, LPS/CD14 interactions upregulated HIV-1 
expression in monocytoid tumor cell lines [15, 297], but protected primary 
macrophages from productive infection by HIV-1 in vitro [205].
The work presented herein was aimed at a characterization of HIV-1 
infection in primary macrophages, and particularly at a dissection of the 
mechanisms responsible for the LPS-induced inhibition of HTV-l replication.
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Initial experiments investigated the effects of LPS on the replication of R5 HIV- 
1 isolates in cultures of monocyte-derived macrophages (MDM) isolated from 
normal donors and infected in vitro.
While this work was in progress, the identification of chemokine 
receptors as the coreceptors for HIV-1 entry into CD4+ cells provided a 
molecular basis of the different cellular tropism of different HIV-1 strains. 
However, the ability of X4 viruses to productively infect macrophages 
remained controversial. Because of the implications that susceptibility to 
infection with these viruses has for the role of macrophages in disease 
transmission and progression, this issue was addressed by investigating 
whether CXCR4 is a functional HTV-l coreceptor in MDM.
The final part of this work was predicated on the finding that primary X4 
HIV-1 isolates indeed infect human macrophages, and was aimed at assessing 
whether the protection conferred to macrophages by LPS stimulation extends 
to infection by CXCR4-dependent HIV-1 isolates.
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3 Materials and Methods
3.1 Reagents
Monoclonal antibodies (mAbs) specific for human CXCR4 (12G5) and CCR5 
(2D7) were kindly provided by J. Hoxie and Leukosite Inc., respectively, 
through the AIDS Reagent Project, National Institute for Biological Standards 
and Control. Anti-CD4 mAh Leu 3A, anti-CD14 mAh P9, FITC-conjugated goat 
anti-mouse IgG and isotype controls were purchased from Becton Dickinson 
(Mountain View, CA). rTNF-a, recombinant C-C chemokines (RANTES, MIP- 
la, and MIP-lp) and neutralizing goat polyclonal antibodies against IL-1 
receptor antagonist (IL-IRa: neutralizing dose, ND50 = 5-10 jug/ml), MIP-la 
(ND50 = 10 ng/ml), MIP-lp (ND50 = 40 fig/ml), and RANTES (ND50 = 100-200 
fig/ml) were obtained from R&D Systems (Minneapolis, MN). Neutralizing 
sheep polyclonal antibodies against IFN-a and IFN-p were obtained from 
Biosource International (Camarillo, CA). rSDF-lp was obtained from Upstate 
Biotechnology (Lake Placid, NY). A neutralizing rat anti-human IL-10 mAh 
(J53-19F1, IgG2a) was a kind gift of Dr. J. Abrams (DNAX Research Institute, 
Palo Alto, CA). The mAbs used in the ELISA assay for soluble TNF receptor 1, 
and in the immunofluorescence analysis of membrane TNF-a expression were 
kindly provided by Dr. A. Corti (San Raffaele Scientific Institute, Milan, Italy). 
Concentrations of TNF-a, IL-6 , MIP-la, MIP-lp and RANTES in culture 
supernatants were determined by ELISA (Quantikine, R&D Systems). 
Recombinant IFN-a (specific activity: 3.75 U/ng) was a kind gift from Roche 
Milano Ricerche. IFN-a concentrations in macrophage supernatants were 
assessed by ELISA (Biosource). LPS from S. minnesota and purified goat IgG
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were purchased from Sigma Chemical Co. (St. Louis, MO). Polymyxin B, sulfate 
was purchased from Calbiochem (La Jolla, CA).
The endotoxin content of all cell culture reagents was assessed by the Limulus 
amoebocyte lysate assay (BioWhittaker, Walkersville, MD), and was always 
<0.125 EU/ml.
3.2 Characterization of viral co-receptor usage
Co-receptor usage was characterized using the human glioma cell line U87.CD4 
coexpressing CCR1, CCR2B, CCR3, CCR5 or CXCR4 [326] and osteosarcoma 
GHOST34.CD4 cells transfected with the Bob/gprl5 or 
Bonzo/ STRL33/ TYMSTR genes (kindly provided by D R. Littman, Skirball
Institute, New York, NY). Cells were seeded in 24-well plates at 5x10^ cells/well 
in DMEM-10% ECS and infected 24 hours later with primary isolates and TCLA 
strains (5 ng of virus) overnight. All cell cultures were observed daily for 
cytopathic effects, and p24 Ag secretion was assessed every 3 days during 2 
weeks of culture.
3.3 HIV-1 isolates
HIV-lBa-L was propagated and titrated in MDM. HIV-Ihib used in section 4.1.1. 
was grown and titrated in PBMC cultures. The TCLA strains HIV-Ihib and 
HIV-Imn used in section 4.2.3. were continuously grown and titrated in 
MOLT3 and PM1 cells respectively. Primary viral isolates (HIV-I5508, HIV-16088 
HIV-110005, HIV-1181, HIV-I57, HIV-15233, HIV-127, HIV-126, HIV-I34 and HIV- 
l l 3o) were isolated from PBMC of children infected by their seropositive
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mothers [326]. The hematological and clinical characteristics of the patients are 
presented in table 3.1.
P a tien t CDC
stage
Total blood  
lym phocytes  
(per m m 3)
Blood CD4+ cells 
(per mm 3)
Blood C D8+ cells 
(per m m 3)
Serum p24 Ag  
(p g /m l)
T herapy
5508 A1 10530 1769 6581 0
6088 A1 6437 3347 1609 387
10005 B1 5589 1512 3130 500
181 N A N A N A N A N A N A
57 A3 2759 359 1477 500
5233 B2 5410 909 2516 N A
27 B3 1148 57 517 500 AZT
34 B3 3668 331 1944 250
130 A3 2425 412 1213 300 AZT
Table 3.1 Clinical and hematological characteristics of HIV-1 infected patients
CDC stage indicates the clinical and immunological status of the child at a 
given age, according to the criteria of the 1994 Revised CDC Classification for 
Children. Categories N, A, and B denote children with no, mild, or moderate 
signs or symptoms of HIV-1 infection, respectively. Categories 1, 2, and 3 
include children with no, moderate or severe immune suppression, 
respectively. AZT, zidovudine. NA, not available.
All viruses were propagated and titrated in PBMC cultures obtained from 
healthy blood donors.
Virus stocks were stored at -80°C before use and treated with Rnase-free 
DNase I (20 U/ml; Sigma) for 30 min at room temperature before infection.
3.4 Isolation of monocytes/MDM and HIV-1 infection
PBMC were isolated by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density 
gradient centrifugation from buffy-coat preparations obtained from healthy
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donors. Cells were resuspended in RPMI 1640 (BioWhittaker, Walkersville,
MD) supplemented with 10% AB+ serum (Sigma), 20% PCS (BioWhittaker, 
Walkersville, MD), 2 mM glutamine, 50 jug/ml streptomycin and 100 U /m l
penicillin, and cultured at a concentration of lxl0& cells/cm2 at 37 °C in 12-well 
tissue culture plates (Nunc, Roskilde, Denmark), in a 1 ml volume. To obtain 
monocytes, non-adherent cells were removed after 1 hour, and the remaining 
adherent cells were cultured for 24 hours. To obtain MDM, non-adherent cells 
were removed after 5-7 days by extensive washing with medium.
Monocyte/ MDM preparations contained >90% CD14+ cells, as assessed by 
immunofluorescence.
For infection, MDM were incubated with viral strains (TCID50: 50/106 
cells) in RPMI 1640-20% PCS, in a total volume of 0.5 ml of cell-free viral 
supernatant. After overnight incubation, unbound virus was removed by 
extensive washing, fresh medium (0.5 ml) was added, and cultures were 
further incubated at 37°C. Supernatants were harvested every 3 days for p24 Ag 
detection. Culture medium was fully replaced every 6 days, without washing.
3.5 Isolation of lymphocytes and HIV-1 infection
Normal peripheral blood lymphocytes depleted of monocytes by 2 cycles of 
adherence to plastic were activated by a 3 day incubation with PHA (3 |ig/ml: 
Sigma). The resulting PHA blasts were resuspended at 2.5 x 106 cells/ml in 
medium containing 10% PCS and IL-2 (10 U/ml: Amersham,
Buckinghamshire, UK), and incubated overnight with HIV-1 isolates. 
Subsequently, free virus was removed by washing twice with RPMI 1640, and 
cells (lxl06/ml) were cultured in 12-well plates in the presence of IL-2. Culture
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supernatants were harvested every 3-4 days, and tested for the presence of p24 
Ag by ELISA.
3.6 HIV-1 detection
HIV-1 p24 Ag concentrations in culture supernatants were determined by 
ELISA [252]. Briefly, p24 Ag from a detergent lysate of virions was captured by 
an immobilized anti-p24 Ag polyclonal antibody (D7320: Aalto Bio Reagents, 
Dublin, Ireland). Bound p24 Ag was then detected using an alkaline 
phosphatase-conjugated anti-p24 Ag monoclonal antibody (BC 1071-AP: Aalto 
Bio Reagents) and the AMPAK ELISA amplification system (DAKO A/S. 
Glostrup, Denmark).
RT activity in the supernatants of HIV-infected MDM was assayed as 
described in Ref. [392]. Briefly, 10 \il of cell-free culture supernatants were added 
to 50 jul of a mixture containing poly (A), oligo (dT) (Pharmacia), MgCl2 , and
32p-labeled deoxythymidine 5'-triphosphate (dTTP) (Amersham) in a 96-well 
V-bottom microtiter plate, and incubated for 1.5 h at 37°C. Five ml of the RT 
reaction mixture were then dotted onto DE81 paper (Whatman, Maidstone, 
England), dried, washed and subsequently counted on a microplate 
scintillation counter (Packard Instrument Co., Meriden, CT).
3.7 Preparation of LPS-conditioned and monokine-depleted 
supernatants
LPS-conditioned supernatants were prepared by incubating cultures of normal 
uninfected MDM in the presence or absence of LPS (1 pg/ml). Two days later, 
supernatants were harvested, centrifuged, and stored at -20 °C until used. In
order to deplete LPS-conditioned supernatants of chemokines (MIP-la, MIP-lp, 
RANTES), Petri dishes were coated for 2 h at room temperature with 
neutralizing antibodies in PBS, at concentrations (10-30 gg/ml) expected to 
neutralize the amounts of chemokines found in culture supernatants. Control 
plates were coated with normal goat IgG (55 ng/ml). LPS-conditioned 
supernatants were incubated in the sensitized dishes overnight at 370C, then 
collected and used immediately. Crude supernatants from MDM unstimulated 
or stimulated with LPS (1 gg/ml) were depleted of IFN-a and IFN-p as follows: 
a mixture of sheep polyclonal anti-human IFN-a and IFN-p antibody (at the 
concentration required to neutralize 1000 U/m l of human IFN-a/p) or sheep 
control IgG (50 jig/ml) were incubated with protein G-Sepharose (Pharmacia 
Biotech) for 1 h at room temperature. LPS-conditioned or control supernatants 
were then incubated with the protein G-Sepharose/antibody complex 
overnight at 4°C, collected, centrifuged and used immediately.
3.8 Immunofluorescence
Expression of CD14, CD4, CXCR4 and CCR5 on monocytes and MDM was 
assessed by indirect immunofluorescence using mAb P9, Leu 3A, 12G5, 2D7, 
respectively, or isotype controls.
For indirect immunofluorescence, 0.5 x 106  cells were incubated in 100 \i\ 
of staining buffer (RPMI 1640-10% AB+ serum, with 0.01% sodium azide) 
containing purified mAbs for 30 min at 4°C, washed and further incubated 
with FITC-conjugated goat anti-mouse IgG for 30 min at 4°C Cells were then 
extensively washed and fixed in 4% p-formaldehyde. Percentages of positive 
cells and mean fluorescence intensity (MFI) were analyzed by a FACScan
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(Becton Dickinson) gating on the monocyte population, as defined by forward 
and side light scatter.
3.9 Chemotaxis Assay
Cell migration was assayed in 48-well Trans well TM chambers using a S-gm 
pore size polycarbonate filter membrane (Costar, Cambridge, MA). 
Chemokines were diluted in RPMI 1640 medium containing human serum 
albumin (0.3%) and added to the lower chamber. One hundred \û of a 3x106/ml 
cell suspension were added to the upper chamber. After a 2 hour incubation at 
37°C in 5% CO2 , the filter was removed and the cells migrated in the lower 
chamber were counted using a FACScan (Becton Dickinson) at 60 \d/m in for 30 
seconds. Appropriate gating on the forward and side scatter was used to select 
specific cell types. The chemotactic index represents the ratio between the 
number of cells that migrated in the presence of chemokines and those that 
migrate spontaneously.
3.10 DNA and RNA extraction for competitive PCR amplification
High molecular weight DNA from HIV-1 infected MDM cultures was extracted 
by overnight incubation at 37°C in lysis buffer (100 mM NaCl, 10 mM Tris-HCl, 
25 mM EDTA, 0.5% SDS pH 8.0, 0.3 mg/ml proteinase K) followed by extraction 
with a phenol-chloroform-isoamyl alcohol mixture (25:24:1) and ethanol 
precipitation. Total RNA was extracted according to the guanidine thiocyanate 
procedure [61], and treated with RNase-free DNase I (Boehringer, Mannheim, 
Germany) to remove traces of contaminating DNA. First-strand cDNA 
synthesis was obtained by priming with random hexamers and reverse 
transcription in 20 jul of reverse transcription mix containing 75 mM KC1, 50
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mM Tris-HCl pH 8.3, 3 mM MgCl2, dNTP (Pharmacia: 0.4 mM each), MMLV- 
RT (Promega, Madison, WI: 400 units), RNasin (Promega: 20 units). RNA was 
pre-heated at 65°C for 5 min and incubated with the reaction mix at 37 °C. After 
1 hour, the reaction was stopped by incubation at 95 °C for 5 min and samples 
were cooled on ice.
3.11 Competitive PCR amplification for CCR5 mRNA
Amplification of CCR5 cDNA was performed using primers CKR-9 
(5'CATCATCCTCCTGACAATCG) and CKR-10
(5 'ATGGTGAAGATAAGCCTCACAG). Quantification of CCR5 mRNA levels 
in MDM was carried out by a competitive PCR procedure [71] using a 
competitor DNA fragment carrying the primer recognition sites for p-actin 
(BA1 and BA4) and CCR-5 (primers CKR-9 and CKR-10). A schematic 
representation of this competitor is shown in Figure 4.6, panel A. and its 
construction is described in the legend to Figure 4.6.
Competitive PCR amplifications were carried out by adding to the 
sample increasing concentrations of the competitive templates, in 100  pi of 
PCR buffer (50 mM KC1, 10 mM Tris-HCl, 2 mM MgClz) containing the two 
primers (100 pmol each), the four dNTPs (200 mM each) and 2.5 U of Taq DNA 
polymerase (Perkin Elmer, Emeryville, CA). Samples were submitted to 50 
cycles of amplification with the following cycle profiles: dénaturation at 95°C 
for 30 sec, annealing at 60°C for 30 sec, extension at 72°C for 30 sec. After 
amplification, 10 pi of each PCR reaction were resolved on a 8 % non­
denaturing polyacrylamide gel, visualized under UV light after ethidium 
bromide staining and photographed. Quantification of the amplification 
products was obtained by densitometric scanning.
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3.12 Semiquantitative PCR for HIV-1 Proviral DNA
PCR was performed in PCR buffer (20 mM Tris-HCl pH 8.4, 50 mM KC1, 1.5 
mM MgCh) containing the primers 1 and 211 (100 pmol each) that amplify a 218 
bp fragment from the HIV-1 gag gene, the four dNTPs (200 mM each) and Taq 
DNA polymerase (Gibco-BRL, Gaithersburg, MD: 2.5 U). Samples were 
submitted to 50 cycles of amplification (95°C for 1 minute, 63°C for 1 minute, 
72°C for 1 minute). PCR products were separated on a 1.8% agarose gel, 
transferred to a nylon membrane (Hybond-N+, Amersham, Buckinghamshire, 
UK) and hybridized with a gag-specific 32P-labelled oligonucleotide 
(5'AGGCGACTGGTGAGTACGCCAAAA). In order to normalize for the 
quantity of DNA in each sample, a 441 bp region of the glyceraldehyde-3- 
phosphate dehydrogenase (GAPDH) gene was amplified using primers 5'- 
GGGAAGGTGAAGGTCGGAGTC and 5 -GCTGATGATCTTGAGGCTGTTGTC. 
Results are expressed as the ratio between the intensities of the HIV-1 and 
GAPDH bands, as assessed by scanning densitometry. Each sample was 
amplified in duplicate or triplicate.
57
4 Results
4.1. Analysis of the mechanisms underlying the LPS-induced inhibition 
of HIV-1 replication in human macrophages
Monocyte /  macrophages are critically involved in the immune response to 
bacterial infections. LPS/endotoxin, the major constituent of the cell wall in 
gram-negative bacteria stimulates monocytes /  macrophages to produce 
cytokines and increase expression of cell adhesion molecules. LPS induces 
cellular responses by forming a complex with circulating LPS-binding protein 
and subsequently binding to CD14 [163, 340, 394]. This in turn facilitates the 
interaction of LPS with signaling molecules belonging to the Toll-like receptor 
family [179,197,295, 301]. LPS/CD14 interactions have been shown to result in 
the induction of HIV expression in monocytoid tumor cell lines [15, 297], but to 
protect primary macrophages from productive infection with HIV-1 in vitro 
[28, 205]. Notably, the concentrations of LPS that affect HIV-1 replication in 
vitro can be easily reached in vivo, and may thus affect viral replication in 
HIV patients superinfected with bacteria. When this work started, the 
mechanisms underlying the complex effects of LPS on HIV-1 expression in 
monocytic cells had not been elucidated. We chose to study the effects of LPS 
on HIV-1 expression in cultures of MDM and T cells isolated from normal 
donors, and infected in vitro with different strains of HIV-1.
4.1.1. LPS suppresses HIV-1 replication in macrophage cultures infected in 
vitro
In order to characterize the effects of LPS on the replication of HIV-1 in 
monocytic cells, MDM from normal donors were infected in vitro with the M- 
tropic HIV-1 Ba_L strain, in the presence or absence of LPS (1 pg/ml). Figure 4.1. A 
shows that p24 Ag secretion in untreated MDM cultures rapidly reached high 
levels, that were maintained for over 10 days. In contrast, p24 Ag secretion by
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LPS-treated MDM remained extremely low throughout the culture time. RT 
activity in the same cultures showed a similar pattern (data not shown). Figure 
4.1. B shows that LPS-dependent inhibition of p24 Ag secretion was also 
observed in MDM cultures infected in vitro with HIV-I5508, a primary NSI 
isolate obtained from an asymptomatic HIV-l-infected patient.
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Figure 4.1 LPS suppresses HIV-1 replication in MDM cultures infected in vitro. 
MDM from h ea lth y  donors were infected w ith  H IV -lB a„L (panel A), the primary NSI iso la te  
H IV -I5088 (panel B), or H lV -lin g  (panel D), all at 500 p g /m l, in the presence or absence of LPS 
(1 p g /m l). MDM were w ashed one day later and further cultured, adding LPS every 3 days. 
Culture supernatants w ere harvested daily, and tested for p24 A g secretion by ELISA. The d a ta  
are representative of 10 (panel A), 3 (panel B) and 2 (panel D) independent experim ents. In p an el 
C, M DM  w ere infected w ith HIV-lga-L or HIV-I5508 in the presence of decreasing concentrations 
of LPS. p24 A g secretion w as assessed 5 days after infection.
Figure 4.1.C shows that p24 Ag secretion was inhibited by > 70% using LPS at a 
concentration of 1 ng/ml. Notably, inhibition was still apparent when LPS was 
added at 10 pg/ml, a physiologically significant concentration [297]. 
Interestingly, LPS addition did not inhibit HIV-1 expression in MDM cultures
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infected with the SI laboratory strain, HIV-lniB (Figure 4.1.D). The surprisingly 
high levels of replication of our HIV-lniB in MDM are likely to result from 
multiple passages of the viral stock in human primary PBMC. Addition of LPS 
did not result in significant cell death, nor in apoptosis, as assessed by trypan 
blue or propidium iodide staining (data not shown).
LPS-induced inhibition of HIV-1 replication was dependent on the time 
of addition of LPS to the culture. Figure 4.2 shows that HIV-1 expression was 
completely blocked when LPS was added at the time of infection or 1 day later, 
but was affected less and less when LPS was added 2 or 3 days after infection 
with HIV-1. Notably, viral replication was completely inhibited by pre-treating 
MDM with LPS for 48 h before infection. However, the inhibitory effect of LPS 
pre-treatment was abolished if the cells were washed before virus addition 
(data not shown). These data suggest that LPS interferes with early events in 
HTV-l infection.
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Figure 4.2 LPS-induced inhibition of HIV-1 expression in MDM cultures is 
dependent on the time of addition of LPS. MDM w ere infected w ith  HIV-1 B a-L  (500 
p g /m l), and stim ulated  w ith  LPS (1 p g /m l) at different tim es from the in itia tion  of the culture. 
Culture supernatants w ere harvested  daily , and tested for p24 Ag secretion by ELISA. The d a ta  
represent the mean of 2 independent experim ents.
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4.1.2. CD14 expression is upregulated in LPS-treated, HIV-l-infected 
macrophages
LPS has been shown to up regulate the expression of its own receptor, CD14, in 
whole blood [235]. We therefore asked whether a modulation of CD14 
expression may contribute to the effects of LPS on HIV-1 replication in MDM. 
Immunofluorescence analysis of MDM cultures 2 days after HIV-1 infection 
showed that CD14 expression was upregulated not only in uninfected, LPS- 
treated MDM, but also in in vitro HIV-l-infected, LPS-untreated cells (Figure 
4.3). Interestingly, LPS and HIV-1 synergized in upregulating CD14 expression. 
These data suggest that the combined effects that HFV-l infection and LPS 
stimulation have on CD14 expression may amplify the LPS-induced, CD14- 
mediated suppression of HFV-l replication.
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Figure 4.3 LPS and HIV-1 synergize in upregulating CD14 expression in MDM. 
MDM were infected w ith  H IV -lga-L  (500 p g /m l) in the presence or absence of LPS (1 p g /m l). 
After 2 days of culture, CD14 expression w as assessed by direct immunofluorescence, using 
phycoerythrin-conjugated mAb P9 and an unrelated isotype control. The data are representative  
of 3 independent experiments.
4.1.3. LPS-induced HIV-1 suppression is not mediated by an effect on the 
secretion of IL-6 and TNF-a
A number of cytokines have been described to regulate HIV-1 expression. In 
particular, TNF-a and IL-6 enhance HFV-l replication in acutely infected MDM. 
The HIV-l-inducing effect of TNF-a is mainly, if not exclusively, mediated by 
the activation of N F -kB, which activates LTR-driven viral RNA transcription 
[84]. IL-6 induces expression of viral proteins and RT activity to levels 
comparable to those induced by TNF-a, but unlike TNF-a, does not increase 
significantly the levels of steady-state viral mRNA [292]. We therefore 
investigated whether a decrease in the production of these HIV-1 stimulatory 
cytokines may underlie LPS-dependent inhibition of HFV-l replication in 
MDM. Figure 4.4 shows that LPS-induced IL-6 secretion was vigorous and 
comparable in both uninfected and HIV-l-infected MDM cultures. In contrast, 
infected cultures treated with LPS showed an impairment in their ability to 
sustain TNF-a secretion over time. However, stimulation with LPS released 
high and comparable levels of TNF-a (>40 ng/ml) from uninfected and 
infected cells at the initiation of the culture, prior to removal of unbound
virus. The decrease in TNF-a detected after 2 or more days of culture did not
result from masking by shed soluble TNF receptors, nor from a selective 
up regulation of membrane TNF-a (data not shown). Addition of rTNF-a (10 
and 100 U/ml) did not restore HFV-l expression, as detected by p24 Ag (data not 
shown). Thus, the decrease in TNF-a was not responsible for the inhibitory 
effect of LPS on HIV-1 replication. Loss of sensitivity of HIV-l-infected MDM to 
TNF-a-mediated upregulation of HIV expression, rather than decreased levels 
of TNF-a, may be involved in LPS-induced inhibition of HIV infection. The 
mechanisms involved in TNF-a suppression remain to established.
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Figure 4.4 Effects of LPS stimulation and/or HIV-1 infection on IL-6 and TNF- 
a secretion by M D M . Uninfected or HIV-lBa_L-infected MDM were cultured in the presence 
or absence of LPS (1 p g /m l). LPS w as added to the cultures every 3 days. IL-6 and T N F -a  
concentrations in the supernatants were measured by ELISA. The data are representative of 4 
independent experim ents.
4.1.4. LPS-induced inhibition of HIV-1 replication is mediated by soluble factors 
active on both macrophages and T lymphocytes
The finding that pre-treatment with LPS inhibited HIV-1 infection only if the 
cells were not washed before adding the virus prompted us to investigate 
whether the effects of LPS are mediated by soluble factors. To this purpose, LPS- 
conditioned supernatants were obtained from MDM cultures stimulated with 
LPS for 24 h, and LPS was neutralized by the addition of polymyxin B (15
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gg/ml). Normal MDM were then infected with HIV-1 and cultured either with
LPS, or with these supernatants (100% v/v) in the absence of LPS. Table 4.1 
shows that supernatants from LPS-treated MDM inhibited HIV-1 replication as 
actively as LPS itself, even in the presence of polymyxin B.
Table LPS-induced inhibition of HIV replication in MDM is mediated by the 
release of soluble factors
HFV-l p24 Ag release 
(pg/ml)
Culture Supernatant added Polymyxin Dav4 Day 7
MDM+HIV-1 Nil - 3,209 12,616
MDM+HIV-1 Nil + 3,620 13,917
MDM+HIV-1+LPS Nil - 108 992
MDM+HIV-1+LPS Nil + 2,953 12,408
MDM+HIV-1 Untreated M 0 + 3,048 13,726
MDM+HIV-1 LPS-treated M 0 + 100 300
M DM  from healthy donors were infected in v itro  w ith  H IV -lua-L / in the presence or absence of 
LPS (1 ng/m ), LPS-conditioned supernatants (100% v /v )  or polym yxin  B sulfate (15 pg/m l). 
Supernatants from infected cultures were harvested at different tim e points, and assayed by  
ELISA for p24 A g secretion.
Interestingly, the effect of the soluble inhibitory factor(s) was not MDM- 
specific. Table 4.2 shows that the same LPS-conditioned supernatants also 
suppressed viral expression in T lymphocytes infected with two NSI strains, 
HIV-lfia-L and the primary isolate HIV-ligi. The inhibitory effect of LPS- 
conditioned MDM supernatants on HIV replication in T cells was particularly 
remarkable, because LPS per se had no effect when added directly to purified, 
infected T cells. However, LPS-conditioned supernatants failed to suppress the 
replication of an SI primary isolate, HIV-I5233, in T cells. These results suggest
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that suppressive monokines released by MDM upon stimulation with LPS are
responsible for the observed inhibition of HIV replication.
Table 4.2 Soluble factors released by LPS-treated MDM inhibit the replication o f 
NSI HIV-1 strains in T lymphocytes
HIV-1 p24 Ag release 
  (Pg/ml)
Culture Supernatant added Polymyxin Ba-L 181 5233
T cells+HIV-l - 2,155 8,755 7,057
T cells+HIV-l + 2,355 6,390 7,592
T cells+HIV-l+LPS - 2,344 7,795 6,793
T cells+HIV-l+LPS + 2,086 7,885 7,738
T cells+HIV-l Untreated M 0 + 2,225 8,927 7,462
T cells+HIV-l LPS-treated M 0 + <100 281 7,198
PH A  activated T lym phocytes isolated  from h ealth y  donors were infected in v itro  w ith  2 N S I  
HIV -1 strains, H IV -lga-L  and H I V - l ig i ,  or w ith  an SI strain, H IV -I5233 , in the presence or 
absence of LPS (1 (ig/m l), LPS-conditioned supernatants (100% v /v )  or polym yxin  B sulfate (15 
Hg/ml). Supernatants from infected cultures were harvested 5 days after infection, and assayed  
by ELISA for p24 A g secretion.
4.1.5. C-C chemokines released by LPS-stimulated macrophages mediate the 
suppression of HIV-1 replication
Several monokines have been reported to suppress HTV-l replication. Among 
them, IL-10 blocks HIV replication by inhibiting the secretion of endogenous 
TNF-a and IL-6 [386], cytokines that upregulate HIV expression. IL-IRa, on the 
other hand, is produced by HIV-infected MDM in large excess relative to IL-la 
and -p, and thus effectively counteracts IL-l-mediated induction of HIV 
expression [407]. We tested whether the release of these monokines was 
responsible for the LPS-induced inhibition of HIV-1 expression in MDM. To 
this purpose, neutralizing anti-IL-10 or anti-IL-IRa antibodies were added to 
MDM cultures infected with HTV-l and stimulated with LPS. Figure 4.5 shows 
that addition of neither antibody reversed the suppression of HIV-1 replication 
caused by LPS, thus ruling out a role of IL-10 and IL-IRa in HIV-1 suppression.
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Figure 4.5 Effects of neutralizing antibodies against HIV-1-inhibitory cytokines. 
MDM were infected w ith  H IV -lg a .L  and stim ulated w ith  LPS (1 [ig /m l), in presence or absence 
of neutralizing anti-IL-IRa or anti-IL-10 antibodies (10 p g /m l). Culture supernatants w ere 
harvested daily , and tested for p24 Ag secretion by ELISA. The data represent the mean of 2 
separate experim ents. Control antibodies had no effect on p24 Ag secretion.
CD8+ T lymphocytes release soluble factors that inhibit HIV-1 replication 
in CD4+ T cells in a manner not restricted by the major histocompatibility 
complex [380]. HFV-l inhibition was recently shown to largely depend on the 
presence of the C-C chemokines RANTES, MIP-la and MFP-lp [67], the natural 
ligands of CCR5, the coreceptor for primary NSI strains [5, 93, 100]. In 
preliminary experiments, we therefore assessed whether CCR5 is expressed in 
MDM, and whether stimulation with LPS induces the release of these 
chemokines. Because no specific antibody was available at the time, 
competitive PCR experiments were carried out to quantitate CCR5 mRNA in 
total cDNA isolated from MDM. Quantification was achieved by using a DNA 
fragment that acts as a dual competitor for PCR amplification of both CCR5
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cDNA and p-actin (as an internal standard) (Figure 4.6. A). Figure 4.6. B shows 
that high levels of CCR5 mRNA were expressed by MDM at the time of 
infection. Stimulation with LPS did not upregulate the expression of CCR5 in 
infected MDM (data not shown).
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Figure 4.6 MDM express CCR5 mRNA. Total RNA w as extracted from untreated MDM. 
R N A  sam ples were treated w ith  D N ase I to remove traces of contam inating D N A  and reverse 
transcribed using random hexameric primers. The cD N A  products w ere m ixed to scalar am ounts of 
a synthetic com petitor D N A  fragment containing primer recognition sites for both P-actin and 
CCR5 am plification, and am plified  w ith  the respective primer pairs, (panel A) Schem atic  
representation of the com petitor D N A  fragment used for the quantification of CCR5 and P-actin  
cD N A . The fragment contains a core sequence derived from the human P-actin cD N A , carrying a 
20 bp insertion in the m iddle (black box). A m plification  w ith  the p-actin-specific primer set 
BA1-BA4 detects a 226 bp product on hum an cD N A , and a 246 product from the com petitor D N A . 
To this core sequence, the primer recognition sites for human CCR5 am plification w ere added a t 
the tw o ends (indicated by gray boxes) by re-am plification w ith  com posite prim ers corresponding 
to the CKR-9+BA1 sequence at one end and CKR-10+BA4 at the other end. A m plification  w ith  
CKR-9 and CKR-10 generates a 288 bp fragment from the com petitor tem plate and a 368 bp 
fragm ent from the CCR5 cD N A . (panel B) C om petitive PCR for the quantification of CCR5 and 
p-actin m RNAs. cD N A  sam ples from untreated MDM were m ixed w ith  tenfold d ilution of th e  
com petitor D N A  fragment as indicated, and am plified  w ith  primer sets CKR-9/CKR-10 and 
B A 1/B A 4 for CCR5 and p-actin m RNA quantification. A m plification products w ere resolved by  
PAGE, stained w ith  ethidium  bromide and quantified by densitom etric scanning. According to 
the principles of com petitive PCR, quantification of the target m olecules in the sam ples w as  
obtained by estim ation of the ratio between the am plification products, as reported at th e  
bottom  of each gel. Furthermore, since the same competitor D N A  fragment acts as a com petitor 
for quantification of both CCR5 and P-actin, standardization for m RNA input is obtained by  
estim ating the ratio betw een the tw o m easurem ents, as indicated at the bottom of the Figure. M: 
m olecular w eight markers.
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We next investigated whether stimulation with LPS induces MDM to 
release C-C chemokines. Table 4.3 shows that addition of LPS resulted in 
vigorous production of these C-C chemokines by MDM, both uninfected and 
infected in vitro with HIV.
Table 4.3 C-C chemokine secretion in macrophage cultures
day 2 day 5
MIP-la MIP-lp RANTES MIP-la MIP-lp RANTES
(pg/ml) (pg/ml)
Exp. #1
Nil 1,710 591 198 900 610 190
LPS 39,297 17,164 12,740 2,014 2,302 2,494
HIV 2,040 627 281 1,227 1,612 542
HIV + LPS 34,452 20,253 8,380 2,266 3,719 818
Exp. #2
Nil 380 50 38 1,200 1,300 67
LPS 22,680 37,590 12,080 25,480 47,220 2,279
HIV 1,750 2,330 47 2,960 8,200 75
HIV + LPS 21,710 20,110 8,890 7,440 13,960 332
U ninfected or H IV -lga-L  -infected MDM were cultured in the presence or absence of LPS (1 
H g/m l). LPS w as added to the cultures every 3 days. Supernatants w ere harvested  after 2 and 5 
days of culture. Concentrations of C-C-chemokines in the supernatants w ere m easured by ELISA.
We then investigated whether the C-C chemokines released in LPS-
conditioned supernatants played a role in the inhibition of HIV-1 replication.
Simultaneous neutralization of RANTES, MIP-la and MIP-lp has been shown
to be required to abrogate the HIV suppressive effects of CD8+ T cell 
supernatants. Thus, high concentrations of antibodies are necessary to achieve 
neutralization [67]. Because monocytes and MDM express all types of Fey 
receptors (CD64, CD32 and CD16), the engagement of which is known to
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modulate HIV expression [367], supernatants from LPS-stimulated MDM 
cultures were simultaneously depleted of RANTES, MIP-la and MIP-lp by 
adsorption on specific antibodies immobilized on plastic. After polymyxin B 
was added to neutralize LPS, chemokine-depleted supernatants were added to 
HIV-l-infected MDM from different donors. In the representative experiment 
shown in Table 4.4, LPS-conditioned supernatants completely inhibited p24 Ag 
secretion. Depletion of C-C chemokines neutralized the inhibitory activity of 
the supernatants. In contrast, supernatants adsorbed on control goat IgG were 
almost as inhibitory as the undepleted ones. Our data suggest that the LPS- 
dependent release of HIV-1 suppressive chemokines plays a major role in the 
inhibition of HIV-1 replication in MDM.
Table 4.4 Antibody-mediated depletion of C-C chemokines neutralizes the HIV 
suppressive activity of LPS-conditioned supernatants
HFV-l p24 Ag 
(pg/ml)
Culture
MDM+HIV-1
Supernatant added Polymyxin Depletion
4,516
MDM+HIV-1 - + 4,426
MDM+HIV-1+LPS -  - 597
MDM+HIV-1+LPS + 4,500
MDM+HIV-1 Untreated M 0 + 5,739
MDM+HIV-1 LPS-treated M 0 + 176
MDM+HIV-1 LPS-treated M 0 + anti-chemokines 3,597
MDM+HIV-1 LPS-treated M 0 + normal goat IgG 806
MDM from h ea lth y  donors were infected in vitro  w ith  H IV -1 Ba-L/ in the presence of LPS- 
conditioned supernatants (1 /3  v /v ) ,  undepleted or depleted  of monokines by adsorption cn 
specific neutralizing antibodies or control IgG im m obilized on plastic. Polym yxin B, sulfate w as  
added at a concentration of 15 p g /m l. Supernatants from infected cultures w ere harvested  a fter  
4 days of culture, and assayed by ELISA for p24 A g secretion. The table show s the results of a 
representative experim ent.
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Competitive inhibition of HIV-1 co-receptor utilization by released 
chemokines is expected to result in the inhibition of HIV entry into MDM [5, 
93, 100]. Therefore, we tested the effects of LPS and LPS-conditioned 
supernatants on the early stages of the HFV-l replication cycle by assessing the 
levels of pro viral DNA in MDM incubated with HIV-1 Ba-L for 14 hrs, in the 
presence or absence of LPS and LPS-conditioned supernatants. Pro viral DNA 
copies were assessed by a semiquantitative nested PCR procedure, using two 
primer sets specific for the pol gene [3, 44]. The representative experiment 
shown in Table 4.5 demonstrates that the addition of LPS and LPS-conditioned 
supernatants reduced the number of viral DNA copies by 93% and 90% 
respectively. The finding that LPS treatment suppressed the rate of HIV-1 DNA 
formation at an early time after MDM infection is consistent with the reported 
ability of C-C chemokines to interfere with HIV-1 entry.
Table 4.5 LPS and LPS-conditioned supernatants inhibits early step(s) in the
HIV replication cycle
Sample n°copies % inhibition
HIV 5,860
LPS 407 93
LPS-conditioned supernatants 585 90
M DM  from  healthy donors w ere infected in vitro w ith HIV-1 Ba-L in the presence of LPS (1 
jig /m l) or LPS-conditioned supernatants (100% V /V ). Sem iquantitative PCR for H IV -1  
D N A  w as perform ed on D N A  isolated 14 hrs post-infection. The table show s the number of 
viral D N A  copies per 106 MDM.
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4.1.6. Recombinant C-C chemokines inhibit HIV-1 replication in hum an 
macrophages
In order to assess whether C-C chemokines are sufficient to inhibit HIV-1 
replication in MDM, recombinant RANTES, MIP-la and MIP-1(3 were added to 
HIV-infected MDM, alone or in combination. Figure 4.7 (upper panel) shows 
that a combination of the three chemokines, each at a concentration of 50 
ng/ml, inhibited the replication of HIV-lga-L in infected MDM by 76%. In the 
same experiments, addition of LPS reduced p24 Ag release by 75%. Among the 
three chemokines, RANTES was the most potent, because it inhibited HIV- 
lBa-L infection as efficiently as LPS when used at a concentration of 250 ng/ml. 
Notably, the inhibitory effect of C-C chemokines on HFV-l replication was 
even more pronounced in MDM cultures infected with NSI primary viral 
isolates. Indeed, Figure 4.7 (lower panel) shows that RANTES, MIP-la and 
MIP-lp blocked the replication of HIV-I5508 by > 75% even when used 
individually at a concentration as low as 10 ng/ml. The combination of the 
three chemokines suppressed HIV-I5508 by over 90%. The concentrations of 
recombinant chemokines used in our experiments were physiologically 
significant. Indeed, assessment of the concentrations of endogenous 
chemokines released by MDM during the overnight incubation with virus and 
LPS prior to washing (data not shown) demonstrated that at the time of in 
vitro infection, HIV is exposed to similar amounts of chemokines. These 
results altogether show that recombinant chemokines are sufficient to inhibit 
HIV infection in human MDM.
71
7000
6 0 0 0 -
5 0 0 0 -
4 0 0 0 -
3 0 0 0 -
2000 -
1000 -
0 2 84 6
6000
5 0 0 0 -
3 0 0 0 -
2000 -
1000 -
N i l
LPS
M IP -la
M IP-ip
RANTES
A ll C-C
2 4 6 8
days post-infection
Figure 4.7Recombinant C-C chemokines inhibit HIV-1 replication in hum an  
MDM. MDM from healthy donors w ere infected in vitro w ith  H IV -lB a -L  (top panel) or w ith  
the NSI primary viral iso late H IV -I5508  (bottom panel), in the presence or absence of LPS (1 
p g /m l) and recombinant chem okines. Chem okines w ere added to H IV -lga-L -infected  cultures a t  
a concentration of 250 n g/m l w hen used in d iv id u ally , and 50 ng/m l each w hen used in  
combination. For H lV -lgsog -in fected  cultures, chem okines were used at 10 n g /m l, in d iv id u a lly  
and in combination. Supernatants from infected cultures w ere harvested at different tim e points, 
and assayed by ELISA for p24 Ag secretion.
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4.2 Characterization of the role of CXCR4 in the infection of 
macrophages by X4 HIV-1 isolates
The identification of chemokine receptors as HIV coreceptors provided a 
molecular basis for the different tropism of different HIV-1 strains. In 
particular CCR5, the RANTES, MIP-la and MIP-lp receptor, was shown to 
serve as the main coreceptor for NSI viruses [5, 60, 93, 98, 100] whereas 
CXCR4/fusin, the natural receptor for SDF-1 [33, 273], mediates the entry of SI 
HTV-l strains, both primary and TCLA [120].
While the lack of CCR5 expression on most T cell lines [396] offered a 
rationale for the inability of NSI strains to infect these cells, the issue of MDM 
infection by HTV-l strains with an SI phenotype remained unresolved. 
Although macrophages express significant levels of CXCR4 on their 
membranes [240], this coreceptor was assumed to be non-functional for 
infection [406]. Because of the critical role of macrophages in the pathogenesis 
of HTV-l infection, we addressed this apparent paradox by infecting normal 
human MDM in vitro with a panel of primary HTV-l isolates and TCLA strains 
rigorously characterized for coreceptor usage. Furthermore, we added the 
natural CXCR4 ligand, SDF-1, to specifically block CXCR4-mediated viral entry.
4.2.1. CXCR4 expression on human macrophages
As a first step in assessing the role of CXCR4 in MDM infection by SI HIV-1 
isolates, we analyzed CXCR4 expression on monocytes and MDM from normal 
donors. Figure 4.8 shows that immunofluorescence with mAb 12G5 detected 
variable but significant levels of CXCR4 protein on monocytes one day after 
isolation, as assessed by both percentage of positive cells and MFI. Although 
culture-induced differentiation resulted in a progressive decrease of CXCR4, 
the receptor was expressed at comparable intensity on MDM at the time of 
infection (day 5 of culture, MFI: 20-29) and on MOLT-3 cells, a T cell line widely 
used to expand SI HTV-l strains (MFI: 24).
culture 
times by 
indirect im
m
unofluorescence 
[377] using 
mAb 
12G5 
and 
2D7, 
respectively.
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The expression of the other major HIV-1 coreceptor, CCR5, followed a similar 
pattern in all donors examined (n=3).
4.2.2. CXCR4 is a functional chemokine receptor in human macrophages at the 
time of in vitro infection
In order to assess the functional activity of CXCR4 on MDM at the time of in 
vitro infection, we evaluated SDF-1 mediated macrophage migration and, as a 
control, the chemoattractant activity exerted by RANTES, a natural ligand for 
CCR5. At day 1 from isolation, SDF-1 induced chemotaxis of hum an 
monocytes over a wide concentration range. Notably, the levels of CXCR4 
available on MDM at day 5 (the time of in vitro  infection) were still sufficient 
to support a brisk chemotactic response to recombinant SDF-1 (Figure 4.9 left 
panel). RANTES-induced chemotaxis was in a comparable range (Figure 4.9 
right panel). These results show that, at the time of virus exposure, CXCR4 is 
not only expressed on MDM at substantial levels, but is fully functional.
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Figure 4.9 Chemotactic activity of SDF-1 and RANTES on monocyte! 
macrophages. The chemotactic index represents the ratio between the number of cells that 
migrated in the presence of chemokines and spontaneous migration. The figure shows the results 
of 1 representative experiment out of 3.
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4.2.3. Primary CXCR4-dependent HIV-1 isolates infect macrophages 
productively and are specifically blocked by SDF-1
In order to define the role of CXCR4 in MDM infection by HIV-1, we selected 
from a panel of 33 primary HIV-1 isolates rigorously characterized for 
coreceptor usage [326] 3 isolates that use exclusively CXCR4, together with a 
control group of 3 CCR5-dependent isolates. As expected, MDM were efficiently 
infected by primary NSI HIV-1 isolates. In a representative experiment, p24 Ag 
levels 9 days post-infection of cultures with HIV-I5508, HIV-16088 and HIV- 
110005 were 5.6, 2.3, and 7.2 ng/ml, respectively. Notably, MDM were efficiently 
infected also by all the CXCR4-dependent primary SI strains, with p24 Ag 
release rapidly reaching substantial levels (Figure 4.10, panel A). The source of 
HIV in our cultures were likely to be MDM, rather than contaminating T cells. 
Indeed, when non-adherent CD3+/CD14- cells were infected with the same 
isolates 5 days after purification, no p24 Ag secretion was ever detected in spite 
of intense surface expression of CXCR4 (data not shown).
SDF-1 has been recently shown to be the natural ligand for CXCR4 but 
not for the other chemokine receptors that mediate HIV-1 fusion and entry [33, 
273]. In order to formally prove that CXCR4 acts as a coreceptor for MDM 
infection by primary SI HIV-1 isolates, we infected MDM in the presence or 
absence of rSDF-1 (2 jug/ml). Figure 4.10 (panel B) shows that addition of rSDF-1 
blocked the replication of all the CXCR4-dependent primary HFV-l strains. 
SDF-l-dependent inhibition of MDM infection was even more efficient than 
that previously observed with human PBMC [326].
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Figure 4.10 Primary CXCRl-dependent HIV-1 isolates infect MDM and are 
specifically blocked by SDF-1. (A) MDM from h ea lth y  donors were infected w ith  prim ary  
CXCR4-dependent isolates (H IV -I27, H IV -I34 and H IV -I130). The Figure show s results 
obtained in 1 representative experim ent out of 15. (B) SDF-1 (2 pg/m l: grey bars) and RANTES  
(100 ng/m l: w h ite  bars) were added at the time of infection and then every 3 days. The Figure 
show s the decrease (%) in p24 Ag secretion in chem okine-treated cultures at day 7 (mean of 3 
experim ents). (C) The effect of SDF-1 (grey bars) and RANTES (w hite bars) cn viral entry w as  
assessed by sem iquantitative PCR. The Figure show s the decrease (%) in pro viral D N A  (H IV - 
1 /G A P D H  ratio) 14 hours post-infection (mean of 2 experiments).
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Semiquantitative PCR analysis (Figure 4.10, panel C) revealed an SDF-1- 
induced decrease in proviral DNA 14 hours after infection that pointed to a 
block at the level of viral entry. By contrast, SDF-1 had no inhibitory effect on 
infection by CCR5-dependent HIV-1 isolates (data not shown).
Consistent with the selective use of CXCR4 as a coreceptor for entry, 
addition of the CCR5 ligand RANTES at a concentration (100 ng/ml) that 
completely inhibits infection with NSI isolates (26) did not affect the entry or 
the replication of CXCR4-dependent HFV-l isolates (Figure 4.10, panels B and 
C). These data demonstrate that CXCR4 is a functional coreceptor for the entry 
of primary HFV-l SI isolates in MDM. Further supporting this conclusion. 
Table 4.6 shows that MDM from a ccr5A32 homozygous individual could be 
infected by 2 HFV-l primary isolates (HIV-I34 and HFV-l 130) that use selectively 
CXCR4, as well as by a primary isolate (HIV-I57) that uses both CXCR4 and 
CCR5. Addition of SDF-1 efficiently blocked HIV infection by all viruses. By 
contrast, RANTES had no significant effect (data not shown).
These results altogether show that CXCR4 supports CCRS-independent 
HFV-l entry in macrophages.
Table 4.6 Primary SI HIV-1 isolates infect CCR5-null MDM and are specifically 
blocked by SDF-1
HIV-1 isolates Coreceptors SDF-1 p24 Ag (pg/ml)
Day 5 Day 9
34 CXCR4 - 4,299 ND
+ 696 ND
130 CXCR4 - 1,546 7,405
+ < 100 145
57 CXCR4, CCR5 - 792 1,889
+ < 1 0 0 < 1 0 0
An in d iv id u al hom ozygous for the ccr5A32 m utation w as identified  by R T-PCR-m ediated
am plification  of cD N A  isolated from MDM using primers previously described [377] The  
m utation w as confirmed by direct sequencing of the PCR product. CCR5A32 MDM w ere infected  
w ith  prim ary HIV-1 isolates, in the presence or absence of rSDF-1 (2 p g /m l). SDF-1 w as added  
every 3 days. p24 A g secretion in culture supernatants w as determ ined by ELISA.
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4.2.4. Infection of MDM by CXCR4-dependent TCLA HIV-1  strains
We then compared the ability of CXCR4-dependent TCLA strains and primary 
isolates to productively infect MDM. Proviral DNA was assessed 14 hours post­
infection with 2  TCLA strains (HIV-Ihib and HIV-Imn grown in MOLTS and 
PM1 cells respectively) and 3 primary isolates (HIV-127, HIV-I34, HIV-1130). 
Table 4.7 shows that the level of viral entry was variable but overall 
comparable for TCLA strains and primary isolates. However, productive 
infection could not be detected with TCLA strains, even when entry had 
occurred with substantial efficiency (e.g., HIV-Ihib for donor 1 and HIV-Imn 
for donor 2). These results suggest that low or absent viral replication in MDM 
infected with TCLA HIV-1 strains was due to both entry and post-entry defects.
Table 4.7 Infection 
HIV-1 isolates
of MDM by CXCR4-dependent TCLA strains and primary
HIV-1 isolates: m e MN 130 34 27
Donor 1
HTV/GAPDH 17.3 ND 11.1 ND ND
p24 Ag <0.1 ND 7.1 ND ND
Donor 2
HTV/GAPDH 0.1 0 .8 0.3 0.7 0 .6
p24 Ag 0.1 0.7 23.7 40.4 30.0
Donor 3
HTV/GAPDH <0 .1 0 .2 7.8 10.7 0.3
p24 Ag <0.1 <0.1 15.8 23.3 6.9
M DM  from 3 donors w ere infected w ith  TCLA strains and primary HIV-1 isolates. PCR for H IV -1  
proviral D N A  and G APDH w as perform ed cn D N A  isolated  from MDM 14 hours post-infection . 
The Table show s the ratio betw een the HIV-1 and GAPDH signals, as assessed by scanning 
densitom etry. p24 A g secretion (n g /m l) 14 days after infection w as determ ined by ELISA.
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4.3 LPS inhibits the replication of primary X4 HIV-1 isolates In 
macrophages and T lymphocytes through different mechanisms
As discussed in section 1.3.3 of the Introduction, various microbial pathogens 
and/or their products can directly affect HIV replication. Dual infection of 
individual cells with HIV-1 and herpes virus or human HTLV-1 [109, 339] 
resulted in enhanced expression of HIV. Similarly, HIV-infected cells 
superinfected with or exposed to products of Mycobacterium tuberculosis and 
Toxoplasma gondii [216] showed enhanced expression of HIV. The finding that 
CXCR4 is a functional coreceptor for HIV-1 infection of human macrophages 
prompted us to investigate the effects of bacterial LPS on macrophages infected 
with X4 primary isolates. The rationale for this study was provided by the 
notion that macrophages are the major source of HIV during opportunistic 
infections [275] and CXCR4-dependent viruses commonly emerge at the 
advanced stages of infection when bacterial superinfections can frequently 
occur.
4.3.1 LPS and soluble factors released by LPS-treated macrophages inhibit the 
replication of HIV-1 isolates in MDM irrespective of coreceptor usage
We previously showed that LPS and LPS-conditioned MDM supernatants 
block the replication of R5 HIV-1 isolates in MDM. Inhibition was mediated by 
the release of C-C chemokines, in particular RANTES, MIP-la and MIP-lp, as 
shown by experiments with specific neutralizing antibodies and addition of 
recombinant chemokines [377] (see section 4.1). We then asked whether LPS 
and/or soluble factors released by MDM upon LPS stimulation affect the 
replication of HFV-l isolates that use coreceptors other than CCR5 for entry 
into target cells. Table 4.8 shows that p24 Ag release 7 days post-infection was
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strongly inhibited by addition of LPS (1 ng/ml) to cultures infected by R5 and X4 
HIV-1 isolates, as well as in MDM infected by a viral isolate capable of using 
CCR5, CXCR4 and CCR3. This result appear to be conflicting with the lack of 
LPS-induced suppression of HIV-1^ replication in MDM showed in figure 4.1 
panel D. The explanation is probably related to an uncontrolled, and probably 
too high, concentration of virus used during the overnight infection of 
macrophage cultures in that experiment.
Table 4.8 LPS and soluble factors released by LPS-treated MDM inhibit the 
replication of HIV-1 isolates in MDM irrespective of coreceptor usage
HIV-1 p24 Ag release 
(pg/ml)
HIV-1: R5 R5/X4/R3 X4
Cells LPS Sup PM #10005 #5233 #26 #27 #27* #130
MDM - - 7,180 2,666 3,915 1,081 8,553 2,295
MDM + - <100 306 1,007 200 1,118 330
MDM + - + 7,620 1,836 ND 2,720 9,330 2,565
MDM - M 0 + 4,985 2,942 11,117 ND 9,695 2,615
MDM - LPS/M0 + <100 519 615 <100 252 <100
M DM  from healthy donors or from an in d iv idual hom ozygous for the A32 ccr5 m utation (*) w ere  
infected in vitro w ith  R5 (H IV -liooosX  R5/X4 (H IV -I5233) and X4 (H IV -I26 , H IV -I27 , H IV - 
I 130) HIV-1 prim ary isolates in the presence or absence of LPS (1 p g /m ), LPS-conditioned  
supernatants (1:3, v /v )  or polym yxin B sulfate (PM: 15 p g /m l). Supernatants from infected  
cultures w ere harvested  at day 7, and assayed by ELISA for p24 A g secretion. A ddition  of 
polym yxin  in the absence of LPS had no effect on infection by HIV-1. ND: not determ ined
Inhibition by LPS was specific because it was fully neutralized by polymyxin B 
sulfate, an antibiotic that binds and neutralizes LPS [236]. Interestingly, LPS- 
conditioned supernatants containing polymyxin B induced a comparable 
decrease in p24 Ag secretion irrespective of the coreceptor(s) used by the viral
isolates. These results suggest that the LPS-dependent blockade of HIV-1 
replication was mediated by LPS-released soluble factors.
4.3.2 LPS inhibits the entry of X4 HIV-1 isolates in MDM
In order to determine which steps in MDM infection with X4 HIV-1 isolates are 
inhibited by LPS, we used a semiquantitative PCR [376] to assess levels of 
proviral DNA 14 hours post-infection of MDM exposed to the virus in the 
presence or absence of LPS (1 jug/ml). p24 Ag secretion in the same cultures was 
measured 7 days after infection. Table 4.9 shows that addition of LPS 
dramatically decreased both proviral DNA and p24 Ag levels in MDM cultures 
infected with all the X4 primary viral isolates tested. As expected, entry of an 
R5 isolate was inhibited as well.
Table 4.9 LPS inhibits the entry of X4 HIV-1 isolates in MDM
HIV-1 isolates: #6088
(R5)
#130
(X4)
#26 #27 
(X4) (X4)
HTV/GAPDH
LPS
10.28 11.1 13.9 3.2
+ 3.0 0.7 1.6 0.7
p 24Ag (ng/ml) - 7.3 1.4 3.9 6.3
+ <0.1 0.3 1.0 0.7
M DM  w ere infected w ith  R5 and X4 primary HIV-1 isolates, in the presence or absence of LPS (1 
p g /m l). PCR for HIV-1 proviral D N A  and GAPDH w as performed on D N A  isolated  from MDM  
14 hours post-infection. The Table show s the ratio between the HIV-1 and G APDH  signals, as 
assessed by scanning densitom etry. p24 A g secretion (ng/m l) 7 days after infection w as  
determ ined by ELISA.
These results indicate that LPS stimulation of MDM results in a block of HIV-1 
entry that affects both CCR5- and CXCR4-dependent primary viral isolates.
4.3.3 IFN-a secreted by LPS-stimulated MDM inhibits the replication of X4 HIV- 
1 isolates
The finding of an LPS-dependent inhibition of HIV-1 entry into MDM did not 
rule out the possibility of a concomitant effect of LPS and/or LPS-released
mediators on later stages in the viral life cycle. Indeed, addition of LPS to MDM 
cultures is known to induce the release of several monokines, including IFN- 
ot, a factor which potently inhibits HIV-1 replication by interfering with post­
entry events [177, 360]. We therefore asked whether secretion of IFN-a by LPS- 
stimulated MDM contributed to the suppression of HIV-1 replication observed 
in the presence of LPS and LPS-conditioned supernatants. To this purpose we 
first assessed IFN-a concentrations in the supernatants of MDM cultures 
treated with LPS for 24 hours. In 3 independent experiments, IFN-a levels 
ranged between 1 and 7 ng/ml. Infection with HFV-l did not result in a 
significant release of IFN-a (data not shown). Table 4.10 shows that 
recombinant IFN-a strongly inhibited replication of all the HIV-1 X4 isolates 
tested when added at 1,000 U/ml. However, suppression by more physiologic 
IFN-a concentrations (100 U/ml, i.e. « 27 ng/ml) was less efficient and 
consistent. These results suggest that secretion of IFN-a is one of the 
mechanisms through which LPS blocks infection of macrophages with X4 HIV- 
1 isolates.
Table 4.10 IFN-a blocks the replication of X4 HIV-1 isolates in macrophages
HFV-l p24 Ag release 
( P g /m l)
Culture Sup added PM H IV -126 H IV -127 H IV-127* H IV -I3
HIV-1 - - 3,915 15,206 8,553 2,835
HIV-l+IFN-a (100 U/ml) - ND 3,545 ND 2,906
HIV-l+IFN-a (1000 U/ml) - <500 2,717 483 321
HIV-1 M 0 + 11,117 17,380 9,695 5,053
HIV-1 LPS/M0 + 615 1,212 772 365
M DM  from healthy donors or from an ind iv idual hom ozygous for the À32 ccr5 m utation (*) w ere 
infected in vitro w ith  X4 HIV-1 primary isolates in the presence or absence of LPS (1 p g /m ), LPS- 
conditioned supernatants (1:3, v /v ) ,  polym yxin  B sulfate (PM: 15 p g /m l) or rIF N -a  (100 or 1,000 
U /m l) . Supernatants from infected cultures were harvested at day 7, and assayed by ELISA for 
p24 A g secretion.
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4.3.4 LPS, but not IFN-a, downregulates the expression of the receptor and 
coreceptors for HIV-1 on MDM
Because PCR analysis had provided evidence for an LPS-dependent inhibition 
of the entry of X4 HIV-1 isolates in MDM, we next investigated whether 
addition of LPS or IFN-a affected the expression of CD4 and/or CXCR4, the 
receptor and coreceptor for these viral isolates. To this purpose, MDM were 
incubated in the presence of LPS (1 ng/ml) for 24 hrs, and then assessed for CD4 
and CXCR4 expression by indirect immunofluorescence. Membrane CCR5, 
which is expected to be downregulated by LPS [338] and/or LPS-induced CC- 
chemokines [6, 231], was tested in parallel. Figure 4.11 shows the results 
obtained in one representative experiment. LPS treatment induced a dramatic 
downregulation of CD4 expression in MDM and a marked decrease in CXCR4. 
CCR5 was barely detectable on the surface of LPS-treated MDM, and CD14 was 
strongly enhanced, as previously reported by our group (data not shown) [377]. 
In contrast, figure 4.12 shows that addition of IFN-a had no inhibitory effect on 
CD4 and CXCR4 levels, despite the high cytokine concentration used (1,000 
U/ml). Notably, CCR5 expression was unaffected as well.
These results suggest that downregulation of both CD4 and CXCR4 may 
be an important mechanism underlying the LPS-dependent block in the entry 
of HFV-l X4 isolates in MDM.
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Figure 4.11 Immunofluorescence analysis of CD4 and CXCR4 expression in 
macrophages LPS-stimulated. MDM w ere cultured in the presence or absence of LPS (1 
p g /m l) for 24 h. The viral receptor and coreceptor w ere detected by indirect immunofluorescence 
using mAb Leu 3A  and 12G5, respectively, and an unrelated isotype control. The data are 
representative of 3 independent experim ents.
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4.3.5 IFN-a and LPS-conditioned supernatants, but not LPS, block infection of 
T-lymphocytes by X4 HIV-1 isolates
Human T lymphocytes, the major target of HIV-1 infection in vivo together 
with macrophages, are known to be LPS-unresponsive. However, these cells 
closely interact with macrophages and are thus exposed to their secretory 
products, including the ones induced by LPS during bacterial infections. 
Indeed, we showed that C-C chemokines released by LPS-stimulated MDM 
suppressed infection with R5 isolates in both macrophages and T cells [377]. We 
therefore asked whether infection of T lymphocytes with X4 primary isolates 
could also be affected by the addition of LPS-conditioned supernatants. In 
parallel, we tested the effects of recombinant IFN-a under the same 
experimental conditions. Table 4.11 shows that both soluble macrophage- 
derived factors and IFN-a strongly suppressed infection of T cells with all the 
X4 isolates used. By contrast, LPS per se had no inhibitory effect.
Table 4.11 rIFN-a and soluble factors released by LPS-treated MDM inhibit the 
replication of X4 HIV-1 isolates in T lymphocytes__________________________
HIV-1 p24 Ag release 
(pg/ml)
Culture Sup added Polymyxin HIV-I27 HIV-I34 HIV-I26
PBL+HIV-1 - - 29,358 22,733 31,200
PBL+HIV-1+LPS - - 25,858 24,000 29,016
PBL+HIV-l+IFN-■a - 4,922 7,546 2,209
PBL+HIV-1 M 0 + 30,041 29,233 19,276
PBL+HIV-1 LPS/M0 + 4,478 2,720 3,454
PBL from healthy donors w ere infected in vitro w ith  X4 prim ary HIV-1 isolates in the presence 
or absence of LPS-conditioned supernatants (1:3 v /v ,  w ith  polym yxin  B sulfate, 15 |ig /m l)  and  
rIFN -a (1,000 U /m l) . Supernatants from infected cultures were harvested at day 7, and assayed  
by ELISA for p24 A g secretion.
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4.3.6 Expression of CD4 and CXCR4 on T lymphocytes is not affected by LPS- 
conditioned supernatants or IFN-a
In order to investigate the mechanisms through which IFN-a and LPS-released 
factors suppress the replication of CXCR4-dependent HIV-1 isolates in T- 
lymphocytes, we then tested whether these stimuli could affect the expression 
of CD4 and CXCR4. CCR5 was also assessed, as an internal control. Figure 4.13 
shows the results obtained in one representative experiment out of three. 
Immunofluorescence analysis revealed that expression of CD4, CXCR4 and 
CCR5 was readily detectable in unstimulated cells. IFN-a had no effect on the 
surface levels of the molecules under investigation. Addition of LPS- 
conditioned supernatants, on the other hand, left CD4 and CXCR4 expression 
unaffected, but suppressed CCR5, probably through downmodulation of the 
receptor by LPS-released C-C chemokine ligands [377]. Surface expression of 
CD4, CCR5 and CXCR4 was not modulated by treatment with LPS or 
polymyxin B alone (data not shown). These results show that inhibition of the 
replication of X4 isolates in lymphocytes upon incubation with LPS- 
conditioned supernatants cannot be ascribed to a downregulation of HIV-1 
receptors and coreceptors.
4.3.7 Suppressive factor(s) released by LPS-stimulated MDM but not IFN-a 
block HIV-1 entry in T lymphocytes
The finding that the expression of CD4 and CXCR4 in T cells was not 
downmodulated upon treatment with LPS-conditioned supernatants suggested 
that different mechanism(s) may be involved in the LPS-dependent inhibition 
of HIV-1 infection in monocytes and T cells. Therefore, we tested whether 
HTV-l entry in T lymphocytes was affected by LPS-derived soluble suppressive 
factors. To this purpose, we assessed levels of proviral DNA in T lymphocyte 
cultures incubated with primary X4 isolates for 14 h in the presence or absence 
of LPS-conditioned supernatants or IFN-a.
figure 
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Table 4.12 shows that LPS-conditioned supernatants, but not IFN-a, strongly 
decreased the levels of HIV-1 proviral DNA 14 h post-infection. By contrast, 
both stimuli inhibited p24 Ag secretion at 10 day from infection.
Table 4.12 Entry of CXCR4-dependent isolates into primary T lymphocytes is 
inhibited by LPS-conditioned supernatants
Nil LPS-supernatants IFN-a
HIV/GAPDH 43,97 5,04 39,35
p24 Ag 8,735 1,200 1,314
PH A  activated T lym phocytes from a h ealth y  donor w ere infected w ith  prim ary X4 H IV -1  
iso lates. PCR for HIV-1 D N A  and GAPDH w as performed on D N A  isolated  14 hours p ost­
infection. The Table show s the ratio betw een the HIV-1 and GAPDH signals, as assessed by  
scanning densitom etry. p24 A g secretion (ng/m l) 10 days after infection w as determ ined by  
ELISA.
To definitively prove that IFN-a is not sufficient to mediate the complex HIV 
suppressive activity of LPS, supernatants from macrophages stimulated with 
LPS were depleted of both type I interferons (IFN-a and IFN-p) using specific 
antibodies, and then added to PHA activated T lymphocytes infected with X4 
primary isolates, in the presence of polymyxin B. Table 4.13 shows that LPS- 
conditioned supernatants completely inhibited HTV-l replication. Antibody- 
mediated depletion of tipe I IFNs only modestly neutralized the inhibitory 
activity of LPS-conditioned supernatants, and was not significantly more 
effective than depletion mediated by control IgG. The neutralizing activity of 
the antibodies against IFN-a has been tested in a separate experiment (data not 
shown).
These results overall indicate that the release of IFN-a/p may contribute 
to the LPS-induced containment of HTV-l replication. However, LPS-treated
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macrophages appear to secrete additional soluble factor(s) that, unlike IFN-a/p, 
markedly suppress the entry of X4 isolates in both macrophages and T cells.
Table 4.13 Depletion of IFN-a and IFN-p does not neutralize the HIV 
suppressive activity of LPS-conditioned supernatants
HIV-1 p24 Ag 
(pg/ml)
Culture
HIV-1
Supernatant added Polymyxin Depletion
73,600
HIV-1+LPS - - - 65,850
HIV-1+LPS - + - 98,800
HIV-1+ IFN-■a - - 10,080
HIV-1 Untreated M 0 + " 81,400
HIV-1 Untreated M 0 + anti-IFN-a/p 65,625
HIV-1 LPS-treated M 0 + - 1,111
HIV-1 LPS-treated M 0 + anti-IFN-a/p 7,902
HIV-1 LPS-treated M 0 + normal goat IgG 2,020
PH A  activated T lym phocytes from healthy donors were infected in v itro  w ith  the X4 prim ary  
iso lates H IV -126/ hi the presence of LPS-conditioned or unstim ulated supernatants (1 /3  v /v ) ,  
undepleted  or depleted  of IF N -a /p . Polym yxin B, sulfate w as added at a concentration of 15 
p g /m l. p24 A g secretion (n g /m l) 5 days after infection w as determ ined by ELISA.
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5.DISCUSSION
5.1 LPS inhibits infection by R5 HIV-1 isolates in human macrophages
For several years it has been known that stimulation with bacterial LPS 
protects macrophages from productive infection by HIV-1 in vitro [28, 205]. 
Despite the potential implications of this finding for the pathogenesis and 
treatment of HIV infection, the mechanisms responsible for the HIV 
suppressive effect of LPS remained unknown. Our results show that LPS 
stimulates human MDM to release soluble factors - the C-C chemokines 
RANTES, MIP-la and MIP-1|3 - that strongly inhibit HIV replication, not only 
in macrophages but also in T lymphocytes. Furthermore, our data suggest that 
CCR5, the receptor for RANTES, MIP-la and MIP-ip, is the major cofactor for 
the entry of R5/NSI isolates in human macrophages, as well as T cells. This 
hypothesis is supported by a number of findings presented herein: (1) at the 
time of infection, MDM expressed CCR5 at the level of both mRNA and 
surface protein; (2) stimulation with LPS induced the release of endogenous C- 
C chemokines, and reduced viral DNA load in infected MDM by > 90% as early 
as 14 hrs after infection, suggesting an inhibition at the level of viral entry; (3) 
depletion of C-C chemokines strongly reduced the HIV-suppressive capacity of 
LPS-conditioned MDM supernatants; (4) recombinant chemokines at 
physiologically significant concentrations inhibited the replication of HIV-1 
NSI strains in MDM.
The suppressive effect of C-C chemokines on MDM infection by R5 HIV- 
1 strains was also supported by the observation that recombinant RANTES, 
MIP-la and MIP-lp potently inhibited fusion between primary macrophages 
and HIV-lBa-L Env-expressing cells [5]. However, the issue of C-C chemokine-
induced inhibition of HTV-l replication in macrophages was controversial, 
with some groups supporting this possibility [11, 51, 377, 405] and others 
reporting that entry of NSI HTV-l strains into primary macrophages was 
relatively insensitive to C-C chemokines[100, 254, 274, 328, 341]. This 
discrepancy was likely to be caused by differences in experimental conditions, 
such as methods chosen for MDM propagation and stimulation and/or virus 
source and/or readout of the experiments and/or time of addition of 
chemokines relative to virus. Several lines of evidence have linked the
antiviral activity of P chemokines with surface expression of heparan sulfate
proteoglycans (HSPG). Indeed, chemokines are basic proteins that bind avidly 
to negatively charged proteoglycans and this interaction appears to be essential 
for their HTV suppressive effect [274]. In addition, it has been recently reported 
that RANTES, MIP-la, and MIP-lp are secreted by CTL as a macromolecular 
complex containing sulphated proteoglycans [379]. These findings suggest that 
the association between chemokines and HSPGs expressed on the cell surface 
and/or secreted may contribute to the specific binding of RANTES, MIP-la, and 
MTP-lp to CCR5, allowing its downmodulation and thus facilitating a marked
HTV-l inhibition. The different effects of P chemokines in macrophages versus
T cells may be explained by the observation that lymphocytes constitutively 
express cell surface HSPGs. By contrast, proteoglycan expression in 
macrophages is a tightly regulated process that depends on the state of cellular 
differentiation and activation [370]. Indeed, high concentrations of RANTES 
had no antiviral activity when MDM were generated using exogenousv growth 
factors such as macrophage colony-stimulating factor (M-CSF) or 
granulocyte/macrophage (GM)-CSF, whereas lower concentrations strongly 
inhibited infection of MDM obtained by 5-day adherence. Notably,
93
macrophages prepared following these two protocols express different amounts 
of surface proteoglycans, and chondroitin sulfate removal partially abolished 
the antiviral effect of RANTES on MDM cultured for 5 days without other 
stimuli [8].
The observation that RANTES, MIP-la, and MIP-lp suppress HTV-l at 
the level of virus entry provided a rationale for the findings that LPS potently 
stimulates HTV-l replication in the latently infected Ui cells, and induces LTR- 
directed transcription in transfected monocytoid tumor cell lines [15, 297]. 
Indeed, LPS is known to potently activate the cellular transcription factor NF- 
kB that, in turn, stimulates LTR-driven gene expression or virus production by 
cells uniformly infected in a latent state.
While the results obtained with recombinant chemokines clearly show 
that these chemoattractants are sufficient to suppress R5 isolates replication in 
MDM, it is possible that LPS-conditioned supernatants contain additional 
factor(s) with HTV suppressive effects. For example, consistent with previous 
reports [145], we found that IFN-a is released by LPS-stimulated MDM and 
blocks the replication of both R5 and X4 isolates. LPS may affect HTV infection 
of MDM by yet another mechanism, i.e., through a direct and unusually 
sustained downregulation of surface CCR5 expression that results from altered 
recycling of chemokine receptors [128].
5.2 CXCR4 is a functional coreceptor for HIV-1 infection of primary 
macrophages
The availability of assays that determine HTV-l coreceptor usage, and of ligands 
that selectively block HIV entry, provided a rational way out of the pre-existing 
maze of viral phenotypes and nomenclatures, and prompted us to readdress
the issue of macrophage infectability by primary HIV-1 strains with different 
biological properties. Section 4.2 of Results shows that human MDM can be 
efficiently infected by primary HIV-1 isolates that selectively use CXCR4 as a 
coreceptor. This notion is supported by a rigorous characterization of all the 
relevant viral isolates as selective CXCR4 users, by the demonstration that 
CXCR4 is functional in an independent assay (i.e., chemotaxis), and most 
importantly, by the ability of SDF-1, the natural ligand of CXCR4, to prevent 
HTV-l infection. We conclude that MDM support the entry and replication not 
only of R5, but also of X4 primary HTV-l isolates. Our conclusion is consistent 
with analogous results showing that several X4 primary isolates replicated
v
equally well in macrophages with or without CCR5, and were inhibited by 
different ligands for CXCR4, including SDF-1 and the bicyclam derivative 
AMD3100 [343, 403, 404]. Moreover, AMD3100 and SDF-1 were able to block 
infection of A32/A32 CCR5 macrophages by SI strains that used a broad range of 
coreceptors including CCR3, CCR5, CCR8, CXCR4, and BONZO [343]. These 
overall observations strongly imply that, together with CCR5, CXCR4 is the 
predominant coreceptor used for HTV-l infection.
The ability of HTV to efficiently use CXCR4 to infect macrophages has 
clinical implications. In addition to their well established role in the early 
stages of the disease and in viral transmission [245], macrophages are also a 
source of virus during the opportunistic infections that mark the progression 
of HTV-l disease [275] and a target for the CXCR4-dependent HTV-l strains that 
emerge in the late stages of HTV infection [326].
Although CXCR4 was initially cloned by a cDNA library derived from 
primary human macrophages, some studies documented the resistance of 
macrophages to infection by several X4 strains, thus providing an explanation
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for the selective transmission of M-tropic strains during mucosal exposure to 
virus [406]. As for the "chemokine inhibition dilemma", these discrepancies 
have been ascribed to variations in macrophage isolation and culture methods 
[312], temporal modulation of CXCR4 levels during cell culture [264], varying 
sensitivities of different assay systems for coreceptor function or HTV-l 
infection, and, most importantly, to the different biological properties of 
primary X4 isolates and prototype X4 laboratory strains (such as HTV-l^ and 
HlV-lj^g) passaged innumerable times since their initial isolation.
Therefore our findings, together with analogous results from other 
groups, cast some doubt on the traditional definition of HTV-l tropism based 
on infection of cells manipulated by culture conditions, and more generally, on 
the usefulness of thinking about HTV isolates as M- versus T-tropic. In 
particular, the conflicting results obtained with CXCR4-dependent TCLA HTV-l 
strains underline how the cellular tropism of HTV isolates appears to be 
determined by multiple virus/host cell interactions. Blocks have been 
observed at the entry step, and have been ascribed to limited coreceptor 
availability [404] and/or to intrinsic defects in the fusogenic properties of env 
proteins [45, 213]. Post-entry defects have also been described, implicating the 
cellular factors required to activate viral replication [126,183, 327, 342]. In this 
respect, the transcription factors NF-ATc [195] and GATA-3 [402] activate HTV-l 
transcription and replication in T cells, whereas binding of C/EBP proteins to 
the HIV-1 LTR is required for HTV-l replication in MDM [166]. By the same 
token, the HTV-l-encoded protein vpr is important for efficient viral 
replication in primary MDM, but not activated T cells [73]. It is tempting to 
speculate that HTV-l strains continuously grown in T cell lines might become 
highly dependent on T cell-specific transcription factors for their replication.
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and/or might develop mutations in genomic regions critical for replication in 
macrophages. Such events would remain functionally silent as long as the 
virus is passaged in T cells, but would be likely to undermine replication in 
macrophages.
5.3 LPS inhibits the infection of X4 isolates in human macrophages
Because we were able to show that CXCR4 is a functional coreceptor for HIV-1 
not only in T cells but also in macrophages, the evaluation of the role played by 
LPS during infection with X4 isolates became critical for our analysis of 
monocyte/HTV-l interactions. Interestingly, as already observed for R5 viruses, 
we found a strong reduction in the replication of X4 HTV-l isolates following 
LPS stimulation of human macrophages. Furthermore, soluble suppressive 
factor(s) released upon LPS treatment were able to neutralize infection with 
CXCR4-dependent viruses in macrophages as well as T lymphocytes. Infection 
of both cell types appeared to be blocked mainly at the level of entry. HIV 
suppression in macrophages was shown to result in part from the ability of this 
bacterial component to downregulate expression of both CXCR4 and CD4. By 
contrast, surface expression of these receptors was not affected in T 
lymphocytes, suggesting a different mechanism of action. Inhibition of HTV-l 
entry was unrelated to the release of IFN-a/p. Indeed, unlike LPS-conditioned 
supernatants, IFN-a did not reduce proviral DNA levels at early times post­
infection; moreover, depletion of IFN-a/p from LPS-conditioned supernatants 
did not neutralize their inhibitory potential. The observation that supernatants 
from LPS-treated macrophages inhibit cell entry of X4 isolates, together with 
the finding that macrophages did not secrete SDF-1 (the only known natural 
ligand for CXCR4) strongly points to the existence . of additional soluble
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suppressive factor(s) so far uncharacterized. The nature of these potential HIV- 
suppressive molecule(s) is currently under investigation.
In this regard,-some papers reported enhanced secretion of macrophage- 
derived chemokine (MDC) upon LPS stimulation [311]. This p chemokine was 
identified based on its ability to block replication of both R5 and X4 HIV isolates 
in PBMCs [277] and therefore was a suitable candidate to mediate the effects of 
LPS. Nevertheless, the inhibitory activity of MDC is still controversial, ’because 
it has been detected by one group using synthetic MDC, but not by others (us 
included) using recombinant forms of the protein [217]. The mechanism 
through which MDC would inhibit both K5 and X4 isolates also remains 
elusive. Indeed, the only known receptor for MDC is CCR4 [186J, a molecule 
that does not appear to have HTV coreceptor activity. Last but not least, unlike 
LPS-derived factors, MDC has been reported to affect post-entry steps in the 
HTV cycle. Thus it is unlikely that MDC release accounts for the LPS-dependent 
inhibition of HTV infection of T cells and macrophages observed in our 
experiments, since cell entry appears to be affected in both cell types.
The finding that LPS-stimulated macrophages release soluble factors that 
effectively inhibit HTV replication in both macrophages and T cells may 
prompt a reinterpretation of the role played by bacterial superinfections in the 
pathogenesis and progression of HTV infection. It has been recently shown that 
CD14 is not just the receptor for LPS of gram negative bacteria [394], but is a 
pattern recognition receptor for foreign lipoglycans of gram positive bacteria 
and mycobacteria as well [208, 300]. Thus, a vast array of exogenous stimuli 
derived from microbial pathogens may conceivably trigger intense chemokine 
release. In this perspective, the effect of bacterial superinfections in patients 
with HTV-l immunodeficiency may be complex and somewhat
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counterintuitive. The chemokine response triggered by the infectious agent 
upon interaction with the host's macrophages may in fact contribute to the 
containment of HTV-l infection in the main targets of the virus, T cells and 
mononuclear phagocytes.
Altogether, the data presented in this thesis may help redefine our 
current understanding of the role played by monocyte/macrophages in the 
pathogenesis of HIV infection. Macrophages have been viewed mostly 
negatively, as major targets for HIV [143, 384], reservoirs for the virus [201, 351], 
triggers for T cell apoptosis [122, 170, 397], and as a source of soluble factors
(TNF-a, IL-1, IL-6) that sustain viral replication [125,292,294]. The potential for
a defensive role of macrophages only became clear after macrophages-derived 
C-C chemokines were shown to exert a potent inhibitory effect on HIV 
replication [67]. These chemoattractants are vigorously secreted not only by
CD8+ T lymphocytes, the cells traditionally implicated in HTV-l suppression, 
but also by activated m onocyte/m acrophages [259]. Therefore, our results raise 
the possibility that macrophages may play a dual role in HTV infection.
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